

# Genetic Testing-Cancer Prevention, Diagnosis and Treatment, Medical 34A

## Table of Content

[Purpose](#)  
[Description & Definitions](#)  
[Criteria](#)  
[Coding](#)  
[Document History](#)  
[References](#)  
[Special Notes](#)  
[Keywords](#)

<a href="#">Effective Date</a>	2/1992
<a href="#">Next Review Date</a>	5/2025
<a href="#">Coverage Policy</a>	Medical 34A
<a href="#">Version</a>	3

**Member-specific benefits take precedence over medical policy and benefits may vary across plans. Refer to the individual's benefit plan for details\*.**

### Purpose:

This policy addresses various single and panel genetic testing for cancer prevention, diagnosis and treatment.

For the most up to date coverage, please refer to Centers for Medicare and Medicaid Services website: [MCD Search \(cms.gov\)](https://www.cms.gov)

### Description & Definitions:

**Hereditary cancer** is a cancer that has developed as a result of a gene mutation passed down from a parent to a child. Inheriting a gene mutation does not necessarily mean that person will develop cancer, but increases their risk. Research and studies have found that certain gene mutations increase the chances of a person to develop certain kinds of cancers, depending on family history, or to respond to certain therapies for cancer, based on the genetic components of the tumor.

**Autosomal recessive:** A genetic condition that appears only in individuals who have received two copies of an autosomal gene, one copy from each parent. The gene is on an autosome, a nonsex chromosome. The parents are carriers who have only one copy of the gene and do not exhibit the trait because the gene is recessive to its normal counterpart gene.

**X-linked recessive inheritance** - hereditary pattern in which a recessive gene on the X chromosome results in the manifestation of characteristics in male offspring and a carrier state in female offspring.

A **first-degree** relative is defined as a relative which includes the individual's parents, full siblings, or children

A **second-degree** relative is defined as a blood relative which includes the individual's grandparents, grandchildren, aunts, uncles, nephews, nieces or half-siblings

A **third-degree** relative is defined as a blood relative which includes the individual's first-cousins, great-grandparents or great grandchildren.

### Criteria:

**Genetic Testing** is considered medically necessary for the prevention, diagnosis and treatment of cancer of patients who meet **ALL** the following:

- There is an approved mutation specific treatment available

- There is sufficient Published Scientific Evidence or 3rd party Consensus in the Medical Community that the results of the specific genetic Testing directs clinical management and improves clinical outcomes;
- After completion of a thorough history, physical examination, pedigree analysis, genetic counseling, relevant diagnostic and biochemical tests (if any), the patient meets criteria for **1 or more** of the following approved tests:
  - **BRCA1 and BRCA 2 and BRCA Analysis Rearrangement Testing (BART)** is medically necessary for **1 or more** of the following:
    - BRCA testing is covered without preauthorization
    - BRCA Analysis Rearrangement Testing (BART) is covered without preauthorization.
    - Additional Genes ATM, CDH1, CHEK2, PALB2, PTEN, STK11, and/or TP53 may be testing in individuals over the age of 18 who meet **1 or more** of the following clinical indications when the test results are used to make clinical management decisions:
      - Biologically-related individual from a family with a known BRCA1, BRCA2, ATM, CDH1, CHEK2, PALB2, PTEN, STK11, and/or TP53 mutation
      - Individual personal history of breast cancer and **1 or more** of the following:
        - Diagnosed at age 45 or younger
        - Diagnosed at age 50 or younger with **1 or more** of the following:
          - An additional breast cancer primary
          - At least one close blood relative with breast cancer at any age
          - At least one close blood relative with epithelial ovarian, fallopian tube, or primary peritoneal cancer
          - At least one close blood relative with pancreatic cancer
          - At least one close blood relative with prostate cancer (Gleason score greater than or equal to 7)
          - An unknown or limited family history (e.g. fewer than two first- or second-degree female relatives or female relatives surviving beyond 45 years in the relevant maternal and/or paternal lineage)
        - Diagnosed at age 60 or younger with a triple negative breast cancer (ER, PR and HER)
        - Diagnosed at any age with **1 or more** of the following:
          - At least one close blood relative with breast cancer diagnosed at age 50 or younger
          - At least two close blood relatives with breast cancer at any age
          - At least one close blood relative with epithelial ovarian, fallopian tube, or primary peritoneal cancer
          - At least two close blood relatives with pancreatic cancer and/or prostate cancer (Gleason score greater than or equal to 7) at any age
          - At least one close male blood relative with breast cancer
          - Individual of Ashkenazi Jewish descent, no additional family history required
    - Individual personal history of epithelial ovarian, fallopian tube, or primary peritoneal cancer at any age
    - Individual personal history of male breast cancer at any age
    - Individual with a personal history of pancreatic cancer at any age, who have at least one close blood relative on the same side of the family with **1 or more** of the following:
      - Breast cancer at age 50 or younger
      - Ovarian cancer at any age
      - Pancreatic cancer at any age
    - Individual of Ashkenazi Jewish descent, no additional family history required;
    - Individual with a personal history of prostate cancer (Gleason score greater than or equal to 7) at any age with at least one close blood relative with **1 or more** of the following:
      - Breast cancer at age 50 or younger
      - Ovarian cancer at any age
      - Pancreatic cancer at any age
      - Prostate cancer (Gleason score greater than or equal to 7) at any age
  - No personal history of breast or ovarian cancer and a family history of first- or second-degree blood relative meeting **any of the above criteria**;

- No personal history of breast or ovarian cancer and a family history of a third-degree blood relative with breast and/or epithelial ovarian/fallopian tube/primary peritoneal cancer with two or more close blood relatives with breast and/or ovarian cancer (with at least one close blood relative with breast cancer prior to age 50).
- Individuals with a combination of breast cancer with **1 or more** of the following:
  - Thyroid cancer
  - Sarcoma
  - Adrenocortical Cancer
  - Endometrial cancer
  - Pancreatic cancer
  - Brain tumors
  - Gastric cancer
  - Leukemia
  - Lymphoma
- **Familial Adenomatous Polyposis (FAP) or attenuated familial adenomatous polyposis (AFAP)** is medically necessary **1 or more** of the following:
  - To confirm the diagnosis of FAP in an affected patient
  - To provide presymptomatic testing for at -risk relatives (first- or second- or third degree relative) of an affected patient
  - To confirm the diagnosis of FAP in those with 10 or more adenomas
  - To provide presymptomatic testing for at -risk relatives (first- or second- or third degree relative) of an affected patient
- **Colaris, COLARIS AP and/or MUTYH, APC, MLH1, MSH2, MSH6, PMS2, EPCAM, MYH** gene testing (1, 2 or 3) must meet **1 or more** of the following criteria:
  - Individual should meet **ALL** of the following criteria based on Amsterdam criteria combined I and II (based on family history)
    - At least three relatives with CRC or with an HNPCC-associated cancer (colorectal cancer, endometrial cancer, ovarian cancer, cancer of the stomach, small bowel, pancreas, ureter or renal pelvis, biliary tract, brain/CNS, sebaceous gland adenomas or keratocanthomas as seen in Muir-Torre syndrome);
    - One member should be a first degree relative of the other two
    - At least two successive generations should be affected;
    - At least one member should be diagnosed with Colorectal Cancer or a cancer associated with Lynch syndrome (colorectal cancer, endometrial cancer, ovarian cancer, cancer of the stomach, small bowel, pancreas, ureter or renal pelvis, biliary tract, brain/CNS, sebaceous gland adenomas or keratocanthomas as seen in Muir-Torre syndrome); before age 50
  - Member should meet **1 or more** of the following criteria based on revised **Bethesda guidelines** (based on **personal history**)
    - Colorectal cancer diagnosed in an individual younger than 50 years;
    - Presence of synchronous or metachronous, colorectal or other Lynch-Syndrome related tumor (colorectal cancer, endometrial cancer, ovarian cancer, cancer of the stomach, small bowel, pancreas, ureter or renal pelvis, biliary tract, brain/CNS, sebaceous gland adenomas or keratocanthomas as seen in Muir-Torre syndrome); regardless of age
    - Colorectal cancer with MSI-high (MSI-H) pathologic –associated features diagnosed in an individual younger than 60 years (i.e, presence of tumor infiltrating lymphocytes, Crohn’s like lymphocytic reaction, mucinous/signet -ring differentiation, or medullary growth pattern);
    - Colorectal cancer or Lynch syndrome-associated tumor (colorectal cancer, endometrial cancer, ovarian cancer, cancer of the stomach, small bowel, pancreas, ureter or renal pelvis, biliary tract, brain/CNS, sebaceous gland adenomas or keratocanthomas as seen in Muir-Torre syndrome); diagnosed in a member AND in at least one first degree relative younger than 50 years;
    - Colorectal cancer or Lynch syndrome-associated tumor (colorectal cancer, endometrial cancer, ovarian cancer, cancer of the stomach, small bowel, pancreas, ureter or renal pelvis, biliary tract, brain/CNS, sebaceous gland adenomas or keratocanthomas as seen in Muir-Torre syndrome); diagnosed in a member AND in at least two first or second degree relatives at any age

- For a member from a family with known high risk syndrome associated with colorectal cancer, with or without known mutation,
  - Member with a desmoid tumor
- Lynch syndrome testing in patients with at least a 5% risk to carry a mutation using **1 or more** of the following Lynch Syndrome Risk Assessment models:
  - PREMM 1,2,6: <http://premm.dfci.harvard.edu/>
  - MMR Predict: <https://webapps.igc.ed.ac.uk/world/research/hnpccpredict/>
  - MMRPro – submit clinical information
- **KRAS and NRAS Testing** is medically necessary for **1 or more** of the following:
  - If currently being considered for treatment with Erbitux® (cetuximab) or Vectibix™ (panitumumab) for colorectal cancer
  - Before beginning Erbitux or Vectibix treatment, either as single medicines or in combination with chemotherapy
  - When first diagnosed with advanced colon or rectal cancer and are planning a treatment strategy
  - Individual with metastatic colorectal Cancer (CRC) needing tumor tissue genotyping for RAS mutations both KRAS and NRAS.
- **Multiple Endocrine Neoplasia Type 1(MEN1) or RET gene** testing is medically necessary for **1 or more** of the following:
  - Clinical suspicion or family history of multiple endocrine neoplasia syndrome, as indicated by **1 or more** of the following
    - Patient with 2 or more endocrine tumors
    - Patient with family history of 2 or more endocrine tumors
    - Patient with "red flag" tumor, as indicated by **1 or more** of the following:
      - Medullary carcinoma of thyroid
      - Pheochromocytoma
      - Parathyroid carcinoma;
      - Paraganglioma
    - MEN1 testing in patient with **1 or more** of the following:
      - Appropriate primary hyperparathyroidism feature, as indicated by **1 or more** of the following
        - Multiglandular hyperparathyroidism;
        - Onset of primary hyperparathyroidism at age 30 years or younger
        - Relative with primary hyperparathyroidism
      - Gastrinoma
      - Multifocal pancreatic endocrine tumors
      - Relative of patient with known MEN1 mutation
- **Medullary Thyroid Cancer and Multiple Endocrine Neoplasia Type 2 (MEN2), RET** testing is medically necessary for **1 or more** of the following:
  - Among members of families with defined RET gene mutations
  - Among members of families known to be affected by inherited medullary thyroid cancer but not previously evaluated for RET mutation
  - In members with sporadic medullary thyroid cancer.
- **Molecular and/or gene expression classifiers for molecular markers for the evaluation of thyroid nodules** for **1 or more** of the following:
  - Thyroid Cancer Mutation Panel (BRAF, RAS, RET/PTC, PAX8/PPAR) when the result of fine needle aspiration sampling of the thyroid nodule is indeterminate
  - Afirma test is considered medically necessary unless there is evidence of the lesion being clearly benign or malignant
  - ThyroSeq Panel is medically necessary for **1 or more** of the following:
    - This test is considered medically necessary when there is a follicular or Hürthle cell neoplasm
    - Atypia of undetermined significance or follicular lesion of undetermined significance
- **Oncotype DX for Breast Cancer - Reverse transcriptase polymerase chain reaction assay for breast cancer gene expression (Oncotype DX)** is indicated when **ALL** of the following are present:
  - Axillary node biopsy is negative for tumor or Tumor is pN0 (node negative) or pN1mi with axillary lymph node micrometastasis less than or equal to 2mm; or with 1-3 positive Axillary Lymph Nodes (ALN) (e.g., Oncotype DX for ductal carcinoma in situ without DCIS recurrence score);

- Newly diagnosed invasive ductal or invasive lobular carcinoma of breast, stage I or II
- The outcome of testing will guide decision making regarding adjuvant chemotherapy;
- Patient is female
- Primary tumor is estrogen receptor-positive
- Primary tumor is HER-2 receptor-negative.
- **TP53 gene testing** for individuals with 1 or more of the following:
  - Individual with a suspected or known clinical diagnosis of Li-Fraumeni syndrome (LFS)
  - Li-Fraumeni-Like syndrome, or a known family history of a P53 mutation
  - Individual whose medical and/or family history is consistent with **1 or more** of the following:
    - A relative with a known deleterious TP53 gene mutation
    - A diagnosis of classic Li-Fraumeni syndrome, defined by **ALL** of the following:
      - Diagnosis of sarcoma before the age of 45 years
      - A parent, child, or full sibling diagnosed with cancer before the age of 45 years;
      - An additional first- or second-degree relative in the same lineage with cancer diagnosed before age 45 years, or a sarcoma at any age;
    - A diagnosis of Li-Fraumeni-Like syndrome defined by **ALL** of the following:
      - Diagnosis of a childhood tumor or sarcoma, brain tumor, or adrenocortical carcinoma diagnosed before age 45 years;
      - A first- or second-degree relative with typical Li-Fraumeni syndrome tumor\* at any age;
      - Another first- or second-degree relative with cancer diagnosed before age 60 years;
    - A diagnosis of breast cancer before age 35 years with a negative BRCA1/2 test especially if there is a family history of sarcoma, brain tumor or adrenocortical carcinoma.
  - For individual with multiple primary tumors, 2 of which are sarcoma, brain or breast cancer and/or adrenocortical cancer before age 36
  - Individual with adrenocortical cancer and choroid plexus ca at any age
- **PTEN Gene testing** should meet criteria for either Operational Diagnosis in member or Operational diagnosis for family where one individual is diagnostic for Cowden Syndrome as evidence by **1 or more** of the following (See below criteria for **Pathognomic Criteria, Major Criteria** and **Minor Criteria** definitions<sup>#</sup>):
  - Operational Diagnosis in individual as evidence by **1 or more** of the following:
    - Mucocutaneous lesions alone with **1 or more** of the following:
      - There are 6 or more facial papules, of which 3 or more must be trichilemmoma;
      - Cutaneous facial papules and oral mucosal papillomatosis
      - Oral mucosal papillomatosis and acral keratoses
      - Palmoplantar keratoses, 6 or more
    - Two or more major criteria but one must include macrocephaly or Lhermitte-Duclos disease (LDD)
    - 1 major and 3 minor criteria
    - 4 minor criteria
  - Operational diagnosis in a family where one person is diagnostic for Cowden syndrome as evidence by **1 or more** of the following:
    - Any pathognomic criterion
    - Any one major criterion with or without minor criteria
    - Two minor criteria
    - History of Bannayan-Riley-Ruvalcaba syndrome
- **MYH-associated polyposis (MAP)** is appropriate when **1 or more** of the following criteria is met:
  - Members with greater than 10 adenomatous colonic polyps; or greater than 15 cumulative adenomas in 10 years and have either
    - Who have a recessive inheritance (family history positive only for siblings)
    - Who have undergone testing for adenomatous polyposis coli (APC) with negative results
  - The asymptomatic siblings of individuals with known MYH-associated polyposis (MAP) and/or Colon Cancer.
- **BCR-ABL mutation analysis** is medically necessary for **1 or more** of the following:

- BCR-ABL and T315-I mutation analysis is covered for the diagnosis and management of members with Philadelphia chromosome positive (Ph+) Chronic Myelogenous Leukemia (CML), or acute lymphoblastic leukemia (ALL)
  - As part of the workup for myelodysplastic syndrome (MDS) myeloproliferative neoplasm (MPN) that includes persistent leukocytosis, thrombocytosis, or cytopenias
  - BCR-ABL mutation other than T315-I for patients considered for treatment with dasatinib (Sprycel®) or nilotinib (Tasigna)
- **Pathfinder TG** is medically necessary for **1 or more** of the following:
  - To be used adjunctively in cases in which a definitive pathologic diagnosis cannot be rendered on a tissue or cytology specimen, either due to inadequate specimen or equivocal histologic or cytologic findings
- **Genetic testing for susceptibility to malignant diseases** not listed above is covered when **ALL** of the following criteria are met:
  - The genetic disorder is associated with a potentially significant cancer or has a lethal natural history;
  - The risk of the type of cancer from the genetic disorder cannot be identified through biochemical or other testing
  - Specific mutation(s) have been established in the scientific literature to be reliably associated with the disease;
  - The results of the genetic test may impact the medical management of the individual;
  - Testing is accompanied by genetic counseling
- **Von Hippel-Lindau syndrome (VHL) gene** testing when **ALL** of the Following:
  - The member displays clinical features, or is at direct risk of inheriting the mutation in question (pre-symptomatic)
  - The result of the test will directly impact the treatment being delivered to the member;
  - After history, physical examination, pedigree analysis, genetic counseling, and completion of conventional diagnostic studies, a definitive diagnosis remains uncertain
- **CBFB/MHY 11(acute myeloid leukemia)** to diagnose acute myelomonocytic leukemia (AML) with abnormal eosinophils covered without criteria.
- **KIT Test (9C Kit/V Kit Hardy Zuckerman Oncogene)** for Gastrointestinal Stromal Tumor (GIST) is covered without criteria.
- **BRAF gene** is covered without criteria.
- **FLT3 (fms-related tyrosine kinase 3)/ CEBPA/ NPM1** (This test may also be ordered as a soft FLDV) is medically necessary for any individual diagnosed with acute myeloid leukemia.
- **STK11** is medically necessary for **All** of the following:
  - Individual with hamartomatous polyps
  - breast cancer with hyperpigmented macules of the lip and oral mucosa
- **CDH1** gene testing is medically necessary for **1 or more** of the following:
  - ≥2 cases of diffuse gastric cancer in first degree relatives, with at least one diagnosed at <50 years
  - ≥3 cases of documented diffuse cancer in first or second degree relatives independent of age of onset
  - Personal history of diffuse gastric cancer diagnosed at <40 years regardless of family history;
  - A personal or family history of diffuse gastric cancer **AND** lobular breast cancer with one diagnosed at <50 years
- **JAK2 (including exons 12 and 13 or JAK2V617F), Myeloproliferative Leukemia gene (MPL), and Calreticulin Mutation Analysis (CALR)** gene testing is medically necessary for **1 or more** of the following:
  - JAK2<sup>V617F</sup>, MPL, and/or CALR for initial testing of clinical and laboratory features suggestive of polycythemia vera
  - Clinical, laboratory, and/or bone marrow features suggestive of essential thrombocytosis
  - Clinical, laboratory, and/or bone marrow features suggestive of primary myelofibrosis (chronic leukemia) or leukocytosis.
  - JAK2 tyrosine kinase mutation (e.g., in exon 12) testing when JAK2<sup>V617F</sup> testing is negative
- **Immuno Globulin Heavy Chain (IGH)** is medically necessary for the diagnosis and management of patients with 1 or more of the following:
  - Multiple Myeloma
  - Status post Bone Marrow /Stem Cell Transplantation
  - Acute myeloid leukemia (AML), also known as acute myelogenous leukemia or acute nonlymphocytic leukemia (AML or ANLL)

- **PML/RAR Alpha (Promyelocytic Leukemia - PML-RAR alpha PCR)** testing for **1 or more** of the following:
  - at the end of consolidation treatment
  - Relapse monitoring – (e.g. every 3 months for 2 years or every 3-6mo for the next 3 years)
  - if a positive test result is obtained, repeat testing from bone marrow in 2-4wks
  - high risk members >60y/o or who had interruptions during consolidation or not able to tolerate maintenance
- **Hereditary retinoblastoma, RB1 Testing** for diagnosis or screening for hereditary retinoblastoma, as indicated by **1 or more** of the following
  - First-degree relative of patient with known RB1 mutation
  - Patient with retinoblastoma, with or without family history of retinoblastoma
- **Calreticulin Exon 9 (CALR) testing** is covered **without** criteria or preauthorization.
- **Epidermal growth factor receptor (EGFR)** [for example, Therascreen] is considered medically necessary as a technique to predict treatment response for individuals with non-small cell, non-squamous cell lung cancer undergoing treatment with EGFR tyrosine kinase inhibitor therapy (for example, erlotinib [Tarceva], gefitinib [Iressa], or afatinib [Gilotrif]).
- **ALK gene** is approved for members with lung cancer or for consideration of treatment of **any** drug which requires ALK gene testing as part of FDA indication.
- **Juvenile polyposis syndrome (JPS SMAD4 and BMPR1A)** is covered for individuals with 1 or more of the following:
  - Have five or more juvenile polyps in the colorectum
  - any juvenile polyps in other parts of the gastrointestinal tract
- **Bladder Tumor Marker Testing (e.g. UroVysion, bladder tumor antigen test, nuclear matrix protein 22 testing (NMP-22), or fibrin/fibrinogen degradation products test)** is considered medically necessary for **1 or more** of the following:
  - Follow-up of treatment for bladder cancer
  - Monitoring for eradication of bladder cancer
  - Recurrences after eradication
- **Bone marrow testing for MYD88 gene mutation** is covered for individuals being evaluated for Waldenström Macroglobulinemia or Lymphoplasmacytic Lymphoma.
- **Hereditary Paraganglioma-Pheochromocytoma (PGL/PCC) Syndrome** testing is medically necessary for **1 or more** of the following:
  - Individual has a first-degree relative with a known SDHB, SDHC, SDHD, or TMEM127 mutation
  - Individual with paraganglioma or pheochromocytoma characterized by **1 or more** of the following:
    - Malignant tumor
    - Previous head and neck paraganglioma (e.g., carotid body tumor)
    - Recurrent tumor
    - Tumor diagnosed before age 45 years
    - Two or more metachronous (diagnosed at different times) tumors
  - Individual with pheochromocytoma without clinical findings suggestive of neurofibromatosis type 1, von Hippel-Lindau syndrome, or multiple endocrine neoplasia type 2.
- **Endopredict Panel Testing** is medically necessary for anyone who has already had the oncotype Dx and is considering additional chemo and/or hormonal therapy where the results would help informed treatment.
- **Percepta Bronchial Genomic Classifier** is medically necessary for **All** of the following:
  - Individual is a current or former smokers
  - Individual is age 21 or greater
  - Individual has a physician-assessed low or intermediate pretest risk of malignancy based upon **1 or more** of the following:
    - Individual is low risk (<10%): Nodules <10mm with <10 pack/year smoking history
    - Individual is intermediate risk (10-60%): Nodules 10-30mm with 10 to 60 pack/year smoking history
  - Individual has had a bronchoscopy that is non-diagnostic (actionable benign or malignant diagnosis cannot be reached)
  - The results from the Percepta Bronchial Genomic Classifier test will be utilized to determine whether computerized tomography (CT) surveillance is appropriate in lieu of further invasive biopsies or surgical procedures as outlined **below**:

**Pre-Test Risk: Post-Test Risk: Post-Test Diagnostic Strategy:**

Intermediate	Intermediate	Proceed to further work up
Intermediate	Low Risk	CT surveillance
Low Risk	Low Risk	CT surveillance
Low Risk	Very Low Risk	CT surveillance

- The test is ordered by physician certified in Percepta Certification and Training Registry (CTR)
- The individual is monitored for malignancy (suggested monitoring includes serial computerized tomography (CT) scans at 3 to 6, 9 to 12, and 18 to 24 months, using thin sections and non-contrast, low-dose techniques)
- The physician will report outcomes in all risk groups including those monitored initially and those who undergo immediate intervention
- Clinical management is consistent with the post-test diagnostic strategy described above in ≥80% of tested individuals
- The physician intends to act upon the test result
- **FoundationOne CDx** is medically necessary for **All** of the following:
  - Next Generation Sequencing (NGS) for Patients with Somatic (Acquired) and Germline (Inherited) Cancer may be covered for **1 or more** of the following:
    - Diagnostic testing of somatic (acquired) cancer when **ALL** of the following criteria are met
      - Patient is appropriate for testing as indicated by **ALL** of the following:
        - Patient has recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer
        - Patient has not been previously tested with same test using next generation sequencing (NGS) for same cancer genetic content
        - Patient has decided to seek further cancer treatment (eg, therapeutic chemotherapy)
      - Diagnostic testing of germline (inherited) cancer when **ALL** of the following criteria are met:
        - Patient is appropriate for testing as indicated by **ALL** of the following:
          - Patient has ovarian or breast cancer
          - Patient has clinical indication for germline (inherited) testing for hereditary breast or ovarian cancer.
          - Patient has risk factor for germline (inherited) breast or ovarian cancer.
          - Patient has not been previously tested with same germline test using next generation sequencing (NGS) for same germline genetic content
  - **Bone Marrow Targeted Genomic Sequencing by Trusight for Acute Myeloid Leukemia** is medically necessary for **All** of the following:
    - MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies may be covered for **ALL** of the following:
      - Test specifically indicated for patient known to have myeloid malignancy at time of testing
      - Patient with appropriate condition, as indicated by **1 or more** of the following:
        - Acute myeloid leukemia
        - Myelodysplastic syndrome
        - Myeloproliferative neoplasms
        - Suspected, but not confirmed, diagnosis of myeloid malignancy and **ALL** of the following:
          - Undefined cytopenia for greater than 4 months
          - Other possible causes have been reasonably excluded
        - Assay performed includes at least minimum genes and positions indicated for its intended use
        - Testing performed on **1 or more** of the following:



- Bone marrow biopsy
  - Bone marrow aspirate
  - Bone marrow clot
  - Peripheral blood sample
  - Extramedullary site suspected of harboring myeloid malignancy
- **Mammaprint** is covered upon request.
- **Oncotype DX Breast Cancer Assay with DCIS recurrence score** is medically necessary when **All** the following clinical conditions are met:
  - Pathology (excisional or core biopsy) reveals ductal carcinoma in situ of the breast (no pathological evidence of invasive disease)
  - FFPE specimen with at least 0.5 mm of DCIS length
  - Individual is a candidate for and is considering breast conserving surgery alone as well as breast conserving surgery combined with adjuvant radiation therapy
  - Test result will be used to determine treatment choice between surgery alone vs. surgery with radiation therapy
  - Individual has not received and is not planning on receiving a mastectomy
- **Decipher<sup>®</sup>** may be covered for **All** of the following:
  - Individual has localized or biochemically recurrent adenocarcinoma of prostate (ie, no clinical evidence of metastasis)
  - Individual has estimated life expectancy of greater than or equal to 10 years.
  - Individual is candidate for and considering (or being considered for) **1 or more** of the following:
    - Conservative management, yet would be eligible for definitive therapy (radical prostatectomy, radiation, or brachytherapy)
    - Radiation therapy, yet would be eligible for addition of brachytherapy boost
    - Radiation therapy, yet would be eligible for addition of short-term androgen deprivation therapy (ADT)
    - Radiation therapy with short-term ADT, yet would be eligible for use of long-term ADT
    - Radiation with standard ADT, yet would be eligible for systemic therapy intensification using next-generation androgen signaling inhibitors or chemotherapy
    - Observation post-prostatectomy, yet would be eligible for addition of post-operative adjuvant radiotherapy
    - Salvage radiotherapy post-prostatectomy, yet would be eligible for addition of ADT
  - Assay performed on formalin-fixed paraffin embedded (FFPE) prostate biopsy tissue with at least 0.5 mm of linear tumor diameter or FFPE tissue from prostate resection specimen.
  - Result will be used to determine treatment according to established practice guidelines.
  - Individual has not received pelvic radiation or ADT prior to biopsy or prostate resection specimen.
  - Individual will be monitored for disease progression according to established standards of care.
- **OncotypDX for Prostate** may be covered by **All** of the following:
  - Individual has localized or biochemically recurrent adenocarcinoma of prostate (ie, no clinical evidence of metastasis).
  - Individual has estimated life expectancy of greater than or equal to 10 years.
  - Individual is candidate for and considering (or being considered for) **1 or more** of the following:
    - Conservative management, yet would be eligible for definitive therapy (radical prostatectomy, radiation, or brachytherapy)
    - Radiation therapy, yet would be eligible for addition of brachytherapy boost
    - Radiation therapy, yet would be eligible for addition of short-term androgen deprivation therapy (ADT)
    - Radiation therapy with short-term ADT, yet would be eligible for use of long-term ADT
    - Radiation with standard ADT, yet would be eligible for systemic therapy intensification using next-generation androgen signaling inhibitors or chemotherapy
    - Observation post-prostatectomy, yet would be eligible for addition of post-operative adjuvant radiotherapy
    - Salvage radiotherapy post-prostatectomy, yet would be eligible for addition of ADT

- Assay performed on formalin-fixed paraffin embedded (FFPE) prostate biopsy tissue with at least 0.5 mm of linear tumor diameter or FFPE tissue from prostate resection specimen.
- Result will be used to determine treatment according to established practice guidelines.
- Individual has not received pelvic radiation or ADT prior to biopsy or prostate resection specimen.
- Individual will be monitored for disease progression according to established standards of care.
- **Prolaris®** may be covered for **ALL** of the following:
  - Needle biopsy with localized adenocarcinoma of prostate (no clinical evidence of metastasis or lymph node involvement)
  - Formalin fixed paraffin-embedded (FFPE) prostate biopsy specimen with at least 0.5 mm of cancer length
  - Individual stage as indicated by **1 or more** of the following:
    - Very Low-Risk Disease as indicated by **ALL** of the following
      - T1c ≤ 6
      - Gleason Score ≤ 6
      - PSA ≤ 10 ng/mL
      - Less than 3 prostate cores with tumor
      - Less than or equal to 50% tumor in any core
      - PSA density of < 0.15 ng/mL/g
      - Test is ordered by physician certified in Myriad Prolaris™ Certification and Training Registry (CTR)
    - Low-Risk Disease with **ALL** of the following:
      - T1-T2a ≤ 6
      - Gleason Score ≤ 6
      - PSA ≤ 10 ng/mL
      - Test is ordered by physician certified in Myriad Prolaris™ Certification and Training Registry (CTR)
    - Favorable Intermediate Risk Disease indicated by **ALL** of the following:
      - Predominant Gleason grade 3 (ie, Gleason score 3+4 = 7)
      - Percentage of positive cores < 50%
      - No more than 1 NCCN intermediate-risk factor (NCCN intermediate-risk factors include T2b to T2c, Gleason score 7, and PSA 10 to 20 ng/mL)
  - Individual has estimated life expectancy of greater than or equal to 10 years.
  - Individual is candidate for and is considering conservative therapy and yet would be eligible for definitive therapy (radical prostatectomy, radiation therapy, or brachytherapy).
  - Result will be used to determine treatment between definitive therapy and conservative management.
  - Individual has not received pelvic radiation or androgen deprivation therapy prior to biopsy.
  - Individual is monitored for disease progression according to established standard of care
- **ProMark® Risk Score** may be covered for **All** of the following:
  - Needle biopsy with localized adenocarcinoma of prostate (no clinical evidence of metastasis or lymph node involvement)
  - Individual stage as indicated by **1 or more** of the following:
    - Very Low-Risk Disease as indicated by **ALL** of the following:
      - T1c ≤ 6
      - Gleason Score ≤ 6
      - PSA ≤ 10 ng/mL
      - Less than 3 prostate cores with tumor
      - Less than or equal to 50% cancer in any core
      - PSA density of < 0.15 ng/mL/g
    - Low-Risk Disease with **ALL** of the following:
      - T1-T2a ≤ 6
      - Gleason Score ≤ 6

- PSA  $\leq$  10 ng/mL
  - Individual has estimated life expectancy of greater than or equal to 10 years.
  - Individual is candidate for and is considering conservative therapy and yet would be eligible for definitive therapy (radical prostatectomy, radiation therapy, or brachytherapy).
  - Individual has not received pelvic radiation or androgen deprivation therapy prior to biopsy.
  - Test is ordered by physician certified in Metamark Genetics Certification and Training Registry (CTR).
  - Individual is monitored for disease progression according to established standard of care
- **ExoDX Prostate (EPI, ExosomeDx Prostate, IntelliScore)** is considered medically necessary once in an individual's lifetime with **1 or more** of the following criteria:
  - Individual with PSA  $>$ 3.0 ng/mL with or without previous benign prostate biopsy
  - Individual with Digital rectal exam suspicious for cancer
- **DecisionDx- Uveal Melanoma (UM)** is covered with **All** of the following:
  - Individual has confirmed diagnosis of uveal melanoma
  - Individual has no evidence of metastatic disease
- **Signatera (liquid biopsy minimal residual disease)** testing is considered medically necessary for **1 or more** of the following:
  - Individual previously diagnosed with Colorectal cancer
- **CSF3R gene** is covered for individual with **ALL** of the following:
  - For tests indicated in patients whom are known to have a MYELOID malignancy at the time of testing, NCD 90.2 applies
  - The patient has a diagnosis of AML, MDS, or MPN unless classified as refractory and/or metastatic cancers and fulfil the NCD 90.2 criteria
  - The test has satisfactorily completed a TA by MolDX® for the stated indications of the test.
  - The assay performed includes at least the minimum genes and positions indicated for its intended use, as described in an associated coverage Article or found in the TA forms
  - For patients that do not have a diagnosis of a MYELOID malignancy, where one is suspected, the patient must have an undefined cytopenia for greater than 4 months, when other possible causes have been reasonably excluded.
  - Testing may be performed on bone marrow biopsies, bone marrow aspirates, bone marrow clots, peripheral blood samples, or extramedullary sites suspected of harboring a MYELOID malignancy.
  - **The test in question will be non-covered if:**
    - Another NGS test was performed on the same surgical specimen/ blood draw (specimen obtained on the same date of service).
    - Testing falls within scope of NCD 90.2 and has been tested with the same test for the same genetic content.
- **DermTech Pigmented Lesion Assay (PLA)** meets criteria for **All** of the following:
  - Diagnosis of melanoma is being considered for pigmented skin lesion.
  - Test ordered by clinician who evaluates pigmented skin lesions and performs biopsies
  - Pigmented skin lesion meets **ALL** of the following characteristics:
    - One or more ABCDE criteria (asymmetry, border, color, diameter, evolving)[D]
    - Primary melanocytic skin lesions between 5 mm and 19 mm
    - Located where skin is intact (ie, non-ulcerated or non-bleeding lesions)
    - Does not contain scar
    - Was not previously biopsied
    - Not located in area of psoriasis, eczema, or similar skin condition
    - Not clinically diagnosed as melanoma (or clinical suspicion is not sufficiently high that treating clinician believes melanoma is more likely diagnosis than not)
    - Located in area other than palms of hands, soles of feet, nails, mucous membranes, or hair covered areas that cannot be trimmed

- Ordering clinician plans (at time of ordering test) to continue to monitor skin lesion for changes if test is negative.
  - Record contains photograph of lesion at time Pigmented Lesion Assay is ordered to allow for appropriate evaluation in subsequent follow-up.
  - Ordering physician clearly documents site on patient's body of lesion.
- **ClonoSEQ** testing is considered medically necessary for individuals with **1 or more** of the following:
  - acute lymphocytic leukemia (ALL)
  - multiple myeloma (MM)
  - chronic lymphoblastic leukemia (CLL)
  - B-Cell Lymphoma
- **Breast Cancer Index (BCI)** testing is considered medically necessary to assess the risk for recurrence in an individual when **All** of the following criteria are met:
  - Individual has undergone surgery and/or full pathological staging prior to testing
  - There is no evidence of distant metastatic breast cancer
  - Breast cancer is nonmetastatic (node negative) or with 1-3 involved ipsilateral axillary lymph nodes
  - Breast tumor is estrogen receptor and/or progesterone receptor positive
  - Breast tumor is HER2 receptor negative
  - Postmenopausal or 50 years of age
  - Patient is a candidate for chemotherapy or endocrine therapy
  - Adjuvant chemotherapy is being considered and this testing is being ordered to assess recurrence risk to guide decision making as to whether or not adjuvant chemotherapy will be utilized
  - No more than one predictive Gene Expression Test for the same breast tumor has been performed
- **PGDx, Genomics solid tumor gene panel** is considered medically necessary for **ALL** of the following:
  - Testing meets National Coverage Determination 90.2, as indicated by **ALL** of the following:
    - Individual diagnosed with **1 or more** of the following:
      - Recurrent cancer
      - Relapsed cancer
      - Refractory cancer
      - Metastatic cancer
      - Advanced cancer (stage III or IV)
    - Individual not previously tested by same test for same genetic content
    - Individual seeking further treatment
  - Test has satisfactorily completed technical assessment by MolDX® for stated indications of test
  - Assay performed includes **ALL** of the following:
    - At least minimum genes and genomic positions required for identification of clinically relevant FDA-approved therapies
    - Companion diagnostic biomarker as well as other biomarkers known to be necessary for clinical decision making for its intended use that can be reasonably detected by test
- **BDX-XL2** may be covered if **ALL** of the following are met:
  - Individual is at least 40 years of age
  - Individual has lung nodule of diameter 8 to 30 mm
  - Pre-test risk of cancer, as determined by Mayo risk prediction algorithm, is 50% or less
- **Guardant360® CDx** comprehensive Liquid Biopsy is medically necessary with **All** of the following:
  - Solid tumor or hematologic tumor type with one or more of the following:
    - Tissue block if available
    - Liquid biopsy if tissue not possible
    - Repeat testing on a new tissue or liquid biopsy for progressive or relapse disease.
- **FoundationOne® Heme** may be covered if 1 or more of the following are met:
  - Solid tumor testing where fusion detection is desired.
  - Hematologic malignancies where fusion detection is desired.
  - Sacromas where fusion detection is desired.

## # Pathognomic Criteria, Major Criteria and Minor Criteria definitions

Pathognomic criteria:

- Mucocutaneous lesions:
  - Trichilemmomas, facial
  - Acral keratoses
  - Papillomatous lesions
  - Mucosal lesions
- Adult Lhermitte-Duclos disease (LDD)(cerebellar tumors)

Major criteria:

- Breast carcinoma
- Follicular thyroid cancer
- Macrocephaly (eg, 97th percentile) (megaloccephaly)
- Endometrial cancer

Minor criteria:

- Other thyroid lesions (eg, goiter, adenomas)
- Mental retardation (ie, IQ < 75)
- GI hamartomas
- Fibrocystic disease of the breast
- Lipomas
- Fibromas
- GU tumors (especially renal cell carcinoma), GU structural manifestations
- Uterine fibroids or malformation
- Colon cancer,
- Esophageal glycogenic acanthosis,
- Papillary or follicular variant of papillary thyroid cancer,
- Testicular lipomatosis,
- Vascular anomalies (including multiple intracranial developmental venous anomalies)

**Effective 2/28/2023, genetic panels of not more than 75 genes are approved for cancer management and treatment. Please disregard any exceptions below that contradict this.**

The following genetic panels are considered **not medically necessary** for any use other than those indicated in clinical criteria, to include but not limited to:

- 4K score
- Ambry's PCDNext panel
- Amsterdam
- Archer DX FusionPlex Kits for blood cancer assays, oncology Research Panel, Thyroid Panel, Solid Tumor Panel, ALK, RET, ROS1 Panel, Sarcoma Panel, NTRK Panel, FGFR Panel, and My Fusion Plex kit
- bioTheranostics Cancer Type ID
- Blueprint™ (also referred to as "80-gene profile")
- Bone Marrow Failure Syndrome
- Breast Cancer Gene Expression Ratio (Theros H/I)
- BreastNext panel,
- BreastOncPX™
- BreastPRS
- Brevagen
- CancerNext Genetic Testing
- Caris Life Sciences panels
- Chemo FX Assay test - Precision Therapeutics
- Chromosome 3 Gene Test for myeloid disorders
- Circulating microRNAs (e.g., miR-1, miR-16, miR-26a, miR-27a, and miR-29a, miR-133a, and miR-199a-5p; not an all-inclusive list)
  - Oncology (thyroid), microRNA profiling by RT-PCR of 10 microRNA sequences, utilizing fine needle aspirate, algorithm reported as a positive or negative result for moderate to high risk of malignancy
  - Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalin-fixed paraffin-embedded tissue, algorithm reported as an expression score
  - MLH1 (mutL homolog 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)
  - MSH2 (mutS homolog 2) (eg, hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)

- MSH6 (mutS homolog 6) (eg, hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)
- PMS2 (PMS1 homolog 2, mismatch repair system component) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)
- Hereditary colon cancer (Lynch syndrome), targeted mRNA sequence analysis panel (MLH1, MSH2, MSH6, PMS2) (List separately in addition to code for primary procedure)
- ColoSeq
- Colonext
- ColonSentry
- ConfirmMDx
- CxBladder
- DecisionDx: all Decision DX tests including Cutaneous Melanoma, Esophageal Cancer, Mesothelioma, and Glioblastoma Multiforme
- DetermaRX
- Digene HPV test
- Duke University Colon Hotspot NGS panel
- Exome Sequence Analysis
- GeneDX OncoGene Dx panel
- Genome Sequence Analysis
- Genomic grade index,
- Immunoscore Colon test
- Insight® DX Breast Cancer Profile
- Know error system (Forensic testing)
- LungLB®
- MammaTyper®
- Mammostrat
- Mammostrat
- Melaris test
- Microculture Kinetic (MiCK) Apoptosis Assays (e.g., Correct Chemo assay)
- MyPRS test
- myPath
- myRisk
- NexCourse® Breast IHC4
- NPI+ and Randox Breast Cancer Array
- NuvoSelect™ eRx 200-Gene Assay
- Oncomap™ ExTra
- Oncotype DX for Colon Cancer
- Oncotype DX for lobular carcinoma in situ (LCIS)
- OnDose
- OvaNext Next Generation Sequencing Panel
- PancreGen panel
- Pathwork Tissue of Origin test or the Pathwork Tissue of Origin test kit
- Percepta Bronchial Genomic Classifier
- Pervenio Lung RS panel
- PreOvar test
- Prosigna Breast Panel
- Rotterdam
- SelectMDx
- SYMPHONY™ Genomic Breast Cancer Profile
- Target Now
- TargetPrint®
- The 41-gene signature assay.
- The 76-gene "Rotterdam signature" assay
- TheraGuide 5-FU
- TheraPrint™
- THEROS Breast Cancer Index
- VeriStrat
- VistaSeq panel
- Whole Exome Sequencing (WES);
- Whole Genome Sequencing

The following genes are considered **not medically necessary** for any use other than those indicated in clinical criteria, to include but not limited to:

- |           |                     |                           |
|-----------|---------------------|---------------------------|
| • ATK1    | • CDK4              | • FBXW7                   |
| • AXIN2   | • CDKN2A            | • FGFR1                   |
| • BAG1    | • CSF1R             | • FGFR2                   |
| • BARD1   | • CTNNA1            | • FGFR3                   |
| • BIRC4   | • CTNNB1            | • FH (fumarate hydratase) |
| • BDX-XL2 | • DDR2              | • FUT3                    |
| • BRIP1   | • ELANE(ELA2 test), | • GALNT12                 |
| • CEACAM6 | • ERBB2             | • GNAQ                    |
| • CDC6    | • ERBB3             | • GNAS                    |
| • CDK2AP1 | • ERBB4             | • GREM1                   |
|           | • ESD               | • Home genetic testing    |

- HRAS
- IDH1/2 Gene
- IGK (Immunoglobulin Kappa Light Chain Locus)
- IL11
- KDR
- KIR TYPING (killer immunoglobulin like receptor)
- LCK
- MAP2K1
- MET amplifications (e.g., cMET)
  - MITF (microphthalmia-associated transcription factor)
  - MRE11
  - MRE11A
- MYCN gene
- NBN
- NOTCH1
- PAM50
- PDGFR
- PIK3CA
- POLD1
- POLE
- PRKAR1A
- PCA3 Gene
- UpM3
- PTCH1
- RAD50
- RAD51C
- RAD51D
- Repeat/Duplicative genetic testing
- RND3
- ROS1 gene mutations
- RPS20
- SEPT9
- SH3BGR
- TCD
- TERT
- TPB
- TRB@/TRG@
- WNT3A
- XRCC2
- YAP

### Coding:

Medically necessary with criteria:

Coding	Description
81162	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and full duplication/deletion analysis (ie, detection of large gene rearrangements)
81163	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis
81164	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)
81165	BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis
81166	BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)
81170	ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (e.g., acquired imatinib tyrosine kinase inhibitor resistance), gene analysis, variants in the kinase domain
81201	APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; full gene sequence
81202	APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; known familial variants
81203	APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; duplication/deletion variants
81206	BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; major breakpoint, qualitative or quantitative
81207	BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; minor breakpoint, qualitative or quantitative
81208	BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; other breakpoint, qualitative or quantitative
81210	BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, colon cancer, melanoma), gene analysis, V600 variant(s)
81212	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; 185delAG, 5385insC, 6174delT

81215	BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant
81216	BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis
81217	BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant
81218	CEBPA (CCAAT/enhancer binding protein [C/EBP], alpha) (e.g., acute myeloid leukemia), gene analysis, full gene sequence
81219	CALR (calreticulin) (eg, myeloproliferative disorders), gene analysis, common variants in exon 9
81235	EGFR (epidermal growth factor receptor) (eg, non-small cell lung cancer) gene analysis, common variants (eg, exon 19 LREA deletion, L858R, T790M, G719A, G719S, L861Q)
81245	FLT3 (fms-related tyrosine kinase 3)
81246	FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia), gene analysis; tyrosine kinase domain (TKD) variants (eg, D835, I836)
81261	IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); amplified methodology (eg, polymerase chain reaction)
81262	IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); direct probe methodology (eg, Southern blot)
81263	IGH@ (Immunoglobulin heavy chain locus) (eg, leukemia and lymphoma, B-cell), variable region somatic mutation analysis
81270	JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, p.Val617Phe (V617F) variant
81273	KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (eg, mastocytosis), gene analysis, D816 variant(s)
81275	KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene) (e.g., carcinoma) gene analysis, variants in codons 12 and 13
81276	KRAS (Kirsten rat sarcoma viral oncogene homolog) (e.g., carcinoma) gene analysis; additional variant(s) (e.g., codon 61, codon 146)
81292	MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis
81294	MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants
81295	MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis
81297	MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants
81298	MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis
81300	MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants
81307	PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; full gene sequence
81308	PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; known familial variant



81301	Microsatellite instability analysis (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) of markers for mismatch repair deficiency (eg, BAT25, BAT26), includes comparison of neoplastic and normal tissue, if performed
81305	MYD88 (myeloid differentiation primary response 88) (eg, Waldenstrom's macroglobulinemia, lymphoplasmacytic leukemia) gene analysis, p.Leu265Pro (L265P) variant
81311	NRAS (neuroblastoma RAS viral [v-ras] oncogene homolog) (e.g., colorectal carcinoma), gene analysis, variants in exon 2 (e.g., codons 12 and 13) and exon 3 (e.g., codon 61)
81315	PML/RARalpha, (t(15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (eg, promyelocytic leukemia) translocation analysis; common breakpoints (eg, intron 3 and intron 6), qualitative or quantitative
81316	PML/RARalpha, (t(15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (eg, promyelocytic leukemia) translocation analysis; single breakpoint (eg, intron 3, intron 6 or exon 6), qualitative or quantitative
81317	PMS2 (postmeiotic segregation increased 2 [ <i>S. cerevisiae</i> ]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis
81318	PMS2 (postmeiotic segregation increased 2 [ <i>S. cerevisiae</i> ]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants
81319	PMS2 (postmeiotic segregation increased 2 [ <i>S. cerevisiae</i> ]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants
81321	PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; full sequence analysis
81322	PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; known familial variant
81323	PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; duplication/deletion variant
81338	MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; common variants (eg, W515A, W515K, W515L, W515R)
81339	MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; sequence analysis, exon 10
81351	TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; full gene sequence
81352	TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; targeted sequence analysis (eg, 4 oncology)
81353	TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant
81401	Molecular pathology procedure, Level 2 – MUTYH, CFBF/MYH11, EML4/ALK
81403	Molecular pathology procedure, Level 4, targeted sequence analysis – EPCAM, <i>VHL</i>
81404	Molecular pathology procedure, Level 5, targeted sequence analysis - KIR, STK11, MEN1
81405	Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25 exons, regionally targeted cytogenomic array analysis) - STK11, RET, SMAD4
81406	Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) - CDH1, MUTYH
81408	Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) - ATM

81432	Hereditary breast cancer-related disorders (e.g., hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); genomic sequence analysis panel, must include sequencing of at least 14 genes, including ATM, BRCA1, BRCA2, BRIP1, CDH1, MLH1, MSH2, MSH6, NBN, PALB2, PTEN, RAD51C, STK11, and TP53
81433	Hereditary breast cancer-related disorders (e.g., hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); duplication/deletion analysis panel, must include analyses for BRCA1, BRCA2, MLH1, MSH2, and STK11
81435	Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis); genomic sequence analysis panel, must include sequencing of at least 10 genes, including APC, BMPR1A, CDH1, MLH1, MSH2, MSH6, MUTYH, PTEN, SMAD4, and STK11
81436	Hereditary colon cancer syndromes (eg, Lynch syndrome, familial adenomatosis polyposis); duplication/deletion gene analysis panel, must include analysis of at least 8 genes, including APC, MLH1, MSH2, MSH6, PMS2, EPCAM, CHEK2, and MUTYH
81437	Hereditary neuroendocrine tumor disorders (eg, medullary thyroid carcinoma, parathyroid carcinoma, malignant pheochromocytoma or paraganglioma); genomic sequence analysis panel, must include sequencing of at least 6 genes, including MAX, SDHB, SDHC, SDHD, TMEM127, and VHL
81438	Hereditary neuroendocrine tumor disorders (eg, medullary thyroid carcinoma, parathyroid carcinoma, malignant pheochromocytoma or paraganglioma); duplication/deletion analysis panel, must include analyses for SDHB, SDHC, SDHD, and VHL
81445	Targeted genomic sequence analysis panel, solid organ neoplasm, DNA analysis, 5-50 genes (eg, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, NRAS, MET, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed
81451	Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis
81455	Targeted genomic sequence analysis panel, solid organ or hematolymphoid neoplasm, DNA analysis, and RNA analysis when performed, 51 or greater genes (eg, ALK, BRAF, CDKN2A, CEBPA, DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MLL, NPM1, NRAS, MET, NOTCH1, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed
81479	Unlisted molecular pathology procedure - RB1 GENE, ProMark
81518	Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 11 genes (7 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithms reported as percentage risk for metastatic recurrence and likelihood of benefit from extended endocrine therapy – Breast Cancer Index
81519	Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 21 genes, utilizing formalin-fixed paraffin embedded tissue, algorithm reported as recurrence score
81521	Oncology (breast), mRNA, microarray gene expression profiling of 70 content genes and 465 housekeeping genes, utilizing fresh frozen or formalin-fixed paraffin-embedded tissue, algorithm reported as index related to risk of distant metastasis (Can be used for MammaPrint)
81522	Oncology (breast), mRNA, gene expression profiling by RT-PCR of 12 genes (8 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence risk score (EndoPredict)

81523	Oncology (breast), mRNA, next-generation sequencing gene expression profiling of 70 content genes and 31 housekeeping genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as index related to risk to distant metastasis (MammaPrint)
81541	Oncology (prostate), mRNA gene expression profiling by real-time RT-PCR of 46 genes (31 content and 15 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a disease-specific mortality risk score
81542	Oncology (prostate), mRNA, microarray gene expression profiling of 22 content genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as metastasis risk score
81546	Oncology (thyroid), mRNA, gene expression analysis of 10,196 genes, utilizing fine needle aspirate, algorithm reported as a categorical result (eg, benign or suspicious) (Afirma)
81599	Unlisted multianalyte assay with algorithmic analysis (PathfinderTG)
86386	Nuclear Matrix Protein 22 (NMP22), qualitative – May also be addressed by Avalon Lab Management
0005U	Oncology (prostate) gene expression profile by real-time RT-PCR of 3 genes (ERG, PCA3, and SPDEF), urine, algorithm reported as risk score - ExosomeDx® Prostate (IntelliScore)
0016U	Oncology (hematolymphoid neoplasia), RNA, BCR/ABL1 major and minor breakpoint fusion transcripts, quantitative PCR amplification, blood or bone marrow, report of fusion not detected or detected with quantitation
0026U	Oncology (thyroid), DNA and mRNA of 112 genes, next-generation sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as a categorical result ("Positive, high probability of malignancy" or "Negative, low probability of malignancy") (Thyroseq)
0037U	Targeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden (FoundationOne CDx™ (F1CDx))
0040U	BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative - MRDx BCR-ABL Test
0045U	Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score (The Oncotype DX® Breast DCIS Score™ Test)
0047U	Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score - Oncotype DX Genomic Prostate Score
0080U	Oncology (lung), mass spectrometric analysis of galectin-3-binding protein and scavenger receptor cysteine-rich type 1 protein M130, with five clinical risk factors (age, smoking status, nodule diameter, nodule-spiculation status and nodule location), utilizing plasma, algorithm reported as a categorical probability of malignancy (BDX- <b>XL2</b> , Bidesix®)
0089U	Oncology (melanoma), gene expression profiling by RTqPCR, PRAME and LINC00518, superficial collection using adhesive patch(es) (Pigmented Lesion Assay (PLA), DermTech)
0239U	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free DNA, analysis of 311 or more genes, interrogation for sequence variants, including substitutions, insertions, deletions, select rearrangements, and copy number variations (FoundationOne® Liquid CDx)

0242U	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA analysis of 55-74 genes, interrogation for sequence variants, gene copy number amplifications, and gene rearrangements – Guardant360 CDx
0250U	Oncology (solid organ neoplasm), targeted genomic sequence DNA analysis of 505 genes, interrogation for somatic alterations (SNVs [single nucleotide variant], small insertions and deletions, one amplification, and four translocations), microsatellite instability and tumor-mutation burden (PGDx elio™ tissue complete)
0287U	Oncology (thyroid), DNA and mRNA, next-generation sequencing analysis of 112 genes, fine needle aspirate or formalin-fixed paraffin-embedded (FFPE) tissue, algorithmic prediction of cancer recurrence, reported as a categorical risk result (low, intermediate, high) - ThyroSeq® CRC
0326U	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA analysis of 83 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden - Guardant360®
0340U	Oncology (pan-cancer), analysis of minimal residual disease (MRD) from plasma, with assays personalized to each patient based on prior next-generation sequencing of the patient's tumor and germline DNA, reported as absence or presence of MRD, with disease-burden correlation, if appropriate - Signatera
0364U	Oncology (hematolymphoid neoplasm), genomic sequence analysis using multiplex (PCR) and next-generation sequencing with algorithm, quantification of dominant clonal sequence(s), reported as presence or absence of minimal residual disease (MRD) with quantitation of disease burden, when appropriate - ClonoSEQ

**Considered Not Medically Necessary:**

Coding	Description
81120	IDH1 (isocitrate dehydrogenase 1 [NADP+], soluble) (eg, glioma), common variants (eg, R132H, R132C)
81121	IDH2 (isocitrate dehydrogenase 2 [NADP+], mitochondrial) (eg, glioma), common variants (eg, R140W, R172M)
81264	IGK@ (Immunoglobulin kappa light chain locus) (eg, leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)
81309	PIK3CA (phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha) (eg, colorectal and breast cancer) gene analysis, targeted sequence analysis (eg, exons 7, 9, 20)
81314	PDGFRA (platelet-derived growth factor receptor, alpha polypeptide) (e.g., gastrointestinal stromal tumor [GIST]), gene analysis, targeted sequence analysis (e.g., exons 12, 18)
81327	SEPT9 (Septin9) (eg, colorectal cancer) promoter methylation analysis
81340	TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (eg, polymerase chain reaction)
81341	TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (eg, Southern blot)
81342	TRG@ (T cell antigen receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)

81345	TERT (telomerase reverse transcriptase) (eg, thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis (eg, promoter region)
81402	Molecular pathology procedure, Level 3, gene rearrangement analysis, evaluation to detect abnormal clonal population
81449	Targeted genomic sequence analysis panel, solid organ neoplasm, 5-50 genes (eg, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, MET, NRAS, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed; RNA analysis
81456	Targeted genomic sequence analysis panel, solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes (eg, ALK, BRAF, CDKN2A, CEBPA, DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MET, MLL, NOTCH1, NPM1, NRAS, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis
81552	Oncology (uveal melanoma), mRNA, gene expression profiling by real-time RT-PCR of 15 genes (12 content and 3 housekeeping), utilizing fine needle aspirate or formalin-fixed paraffin-embedded tissue, algorithm reported as risk of metastasis
0018U	Oncology (thyroid), microRNA profiling by RT-PCR of 10 microRNA sequences, utilizing fine needle aspirate, algorithm reported as a positive or negative result for moderate to high risk of malignancy (ThyraMIR™)
0069U	Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalin-fixed paraffin-embedded tissue, algorithm reported as an expression score (miR-31now™, GoPath Laboratories)
0158U	MLH1 (mutL homolog 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure) (CustomNext + RNA: <i>MLH1</i> )
0159U	MSH2 (mutS homolog 2) (eg, hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure) (CustomNext + RNA: <i>MSH2</i> )
0160U	MSH6 (mutS homolog 6) (eg, hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure) (CustomNext + RNA: <i>MSH6</i> )
0161U	PMS2 (PMS1 homolog 2, mismatch repair system component) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure) (CustomNext + RNA: <i>PMS2</i> )

0162U	Hereditary colon cancer (Lynch syndrome), targeted mRNA sequence analysis panel (MLH1, MSH2, MSH6, PMS2) (List separately in addition to code for primary procedure) CustomNext + RNA: Lynch (MLH1, MSH2, MSH6, PMS2)
0288U	Oncology (lung), mRNA, quantitative PCR analysis of 11 genes (BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, WNT3A) and 3 reference genes (ESD, TBP, YAP1), formalin-fixed paraffin-embedded (FFPE) tumor tissue, algorithmic interpretation reported as a recurrence risk score (DetermaRx™)
0261U	Oncology (colorectal cancer), image analysis with artificial intelligence assessment of 4 histologic and immunohistochemical features (CD3 and CD8 within tumor-stroma border and tumor core), tissue, reported as immune response and recurrence-risk score (Immunoscore®)
0317U	Oncology (lung cancer), four-probe FISH (3q29, 3p22.1, 10q22.3, 10cen) assay, whole blood, predictive algorithm-generated evaluation reported as decreased or increased risk for lung cancer (LungLB®)
0329U	Oncology (neoplasia), exome and transcriptome sequence analysis for sequence variants, gene copy number amplifications and deletions, gene rearrangements, microsatellite instability and tumor mutational burden utilizing DNA and RNA from tumor with DNA from normal blood or saliva for subtraction, report of clinically significant mutation(s) with therapy associations (Oncomap™ ExTra)
0342U	Oncology (pancreatic cancer), multiplex immunoassay of C5, C4, cystatin C, factor B, osteoprotegerin (OPG), gelsolin, IGFBP3, CA125 and multiplex electrochemiluminescent immunoassay (ECLIA) for CA19-9, serum, diagnostic algorithm reported qualitatively as positive, negative, or borderline (IMMray® PanCan-d)

## Document History:

### Revised Dates:

- 2023: December
- 2023: September
- 2023: July
- 2023: February
- 2023: January
- 2022: December
- 2022: November
- 2022: October
- 2022: September
- 2022: August
- 2022: July
- 2022: June
- 2022: March
- 2022: February
- 2022: January
- 2021: November
- 2021: October
- 2021: July
- 2021: June
- 2021: May
- 2021: April
- 2021: February
- 2020: October
- 2020: February
- 2019: August
- 2019: July
- 2016: July
- 2016: May
- 2016: April
- 2016: March
- 2016: February
- 2016: January
- 2015: December
- 2015: November
- 2015: October
- 2015: August
- 2015: July
- 2015: May
- 2015: April
- 2015: February
- 2014: December
- 2014: November
- 2014: October
- 2014: September
- 2014: August
- 2014: July
- 2014: June
- 2014: May
- 2014: April
- 2014: March
- 2014: January
- 2013: October
- 2013: August
- 2013: July
- 2013: June
- 2013: April
- 2013: February
- 2012: November
- 2012: October
- 2012: September
- 2012: July
- 2012: June
- 2012: March
- 2012: February
- 2011: December
- 2011: October
- 2011: September
- 2011: July
- 2011: June
- 2011: April
- 2011: March
- 2010: December
- 2010: July
- 2009: June
- 2009: April

#### Reviewed Dates:

- 2021: April
- 2019: October
- 2016: February
- 2015: February
- 2014: February
- 2010: November

#### Effective Date:

- February 2009

#### References:

Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

(2022, Aug 31). Retrieved Apr 19, 2023, from MCG: <https://careweb.careguidelines.com/ed26/index.html>

(2023). Retrieved May 01, 2023, from Department of Medical Assistance Services: <https://vamedicaid.dmas.virginia.gov/manuals/provider-manuals-library#gsc.tab=0&gsc.q=guardant360&gsc.sort=>

(2023). Retrieved May 01, 2023, from Hayes, Inc: <https://evidence.hayesinc.com/search?q=%257B%2522text%2522:%2522guardant360%2520cdx%2522,%2522title%2522:null,%2522termsource%2522:%2522searchbar%2522,%2522page%2522:%2522%257B%2522page%2522:0,%2522size%2522:50%257D,%2522type%2522:%2522all%2522,%2522sources%25>

Baumli, J., Li, B., Velcheti, V., & Govindan, R. (2022, Apr). Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib. Retrieved May 01, 2023, from PubMed: <https://pubmed.ncbi.nlm.nih.gov/34838325/>

Cell-free DNA Testing for the Management of Cancer 2023-02-12. (2023, Feb 12). Retrieved Apr 20, 2023, from AIM Specialty Health (Carelon Medical Benefits Management): <https://guidelines.carelonmedicalbenefitsmanagement.com/cell-free-dna-testing-for-the-management-of-cancer-2023-02-12/>

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. (2018, Mar 05). Retrieved May 01, 2023, from American Society of Clinical Oncology: <https://ascopubs.org/doi/pdf/10.1200/JCO.2017.76.8671>

Circulating Tumor DNA Panel Testing (Liquid Biopsy). (2023, Feb 23). Retrieved May 01, 2023, from Anthem: [https://www.anthem.com/dam/medpolicies/abcbs\\_va/active/policies/mp\\_pw\\_d082650.html](https://www.anthem.com/dam/medpolicies/abcbs_va/active/policies/mp_pw_d082650.html)

Genetic Testing Collateral Document. (2023, Feb 15). Retrieved May 01, 2023, from Cigna: [https://static.cigna.com/assets/chcp/pdf/coveragePolicies/medical/Genetic\\_Testing\\_Collateral\\_Document.pdf](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/medical/Genetic_Testing_Collateral_Document.pdf)

Guardant360 CDx – P200010/S008. (2022, Sep 12). Retrieved May 01, 2023, from Food and Drug Administration: <https://www.fda.gov/medical-devices/recently-approved-devices/guardant360-cdx-p200010s008>

LCD MoIDX: Plasma-Based Genomic Profiling in Solid Tumors (L38043). (2021, Dec 30). Retrieved Apr 19, 2023, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=38043&ver=9&>

Molecular Oncology Testing for Cancer Diagnosis, Prognosis, and Treatment Decisions. (2023, Apr 01). Retrieved May 01, 2023, from United Healthcare: <https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/molecular-oncology-testing-for-cancer.pdf>

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) with NCCN Evidence Blocks™. (2023). Retrieved Apr

28, 2023, from National Comprehensive Cancer Network: <https://www.nccn.org/guidelines/guidelines-with-evidence-blocks>

NCD: Next Generation Sequencing (NGS) (90.2). (2020, Nov 13). Retrieved May 01, 2023, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=372&ncdver=2&bc=0>

Overman, M., & Morse, M. (2023, Apr 04). Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors. Retrieved Apr 20, 2023, from UpToDate: [https://www.uptodate.com/contents/tissue-agnostic-cancer-therapy-dna-mismatch-repair-deficiency-tumor-mutational-burden-and-response-to-immune-checkpoint-blockade-in-solid-tumors?search=guardant360&source=search\\_result&selectedTitle=1~1&usage\\_type=default](https://www.uptodate.com/contents/tissue-agnostic-cancer-therapy-dna-mismatch-repair-deficiency-tumor-mutational-burden-and-response-to-immune-checkpoint-blockade-in-solid-tumors?search=guardant360&source=search_result&selectedTitle=1~1&usage_type=default)

Pharmacogenetic and Pharmacodynamic Testing. (2023, Apr 27). Retrieved May 01, 2023, from Aetna: [https://www.aetna.com/cpb/medical/data/700\\_799/0715.html](https://www.aetna.com/cpb/medical/data/700_799/0715.html)

Tumor Markers. (2023, Mar 31). Retrieved May 01, 2023, from Aetna: [https://www.aetna.com/cpb/medical/data/300\\_399/0352.html](https://www.aetna.com/cpb/medical/data/300_399/0352.html)

Umemoto, K., Sunakawa, Y., Ueno, M., & Furukawa, M. (2023, Apr). Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer. Retrieved May 01, 2023, from PubMed: <https://pubmed.ncbi.nlm.nih.gov/36782009/>

ClonoSEQ (Adaptive Biotechnologies). (2022, Jun 22). Retrieved Apr 20, 2023, from Hayes, Inc: <https://evidence.hayesinc.com/report/gte.clono3338>

Dna-Based Test For Minimal Residual Disease For Hematologic Malignancies. (2023, Apr 17). Retrieved Apr 20, 2023, from Food and Drug Administration: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=5291>

Genetic Testing - Appropriate Use Criteria: Somatic Tumor Testing. (2023, Feb 12). Retrieved Apr 20, 2023, from AIM Specialty Health (Carelon Medical Benefits Management): <https://guidelines.carelonmedicalbenefitsmanagement.com/wp-content/uploads/2023/03/PDF-Somatic-Tumor-Testing-2023-02-12.pdf>

Hussaini, M., Srivastava, J., & Lik, L. N. (2021, Apr 09). Assessment of Clonotypic Rearrangements and Minimal Residual Disease in Lymphoid Malignancies. Retrieved Apr 20, 2023, from PubMed: <https://discovery.ebsco.com/c/w35cs5/details/2orznpqobb?q=ClonoSEQ>

LCA: Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers. (2023, Jan 01). Retrieved Apr 20, 2023, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=58988&ver=13>

LCD: MolDX: Minimal Residual Disease Testing for Cancer (L39779). (2021, Dec 26). Retrieved Apr 20, 2023, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38779&ver=4&keyword=ClonoSeq&keywordType=starts&areaId=s53&docType=NCA,CA L,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=1>

Gerami, P., Yao, Z., Polisky, D., Jansen, B., Busam, K., Ho, J., . . . Ferris, L. (2017, Jan). Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. Retrieved May 01, 2023, from PubMed: <https://pubmed.ncbi.nlm.nih.gov/27707590/>

LCD MolDX: Pigmented Lesion Assay (L38051). (2021, Dec 23). Retrieved Apr 19, 2023, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=38051&ver=12&>

Marushchak, O., Yakubov, R., Yakubov, R., & Goldenberg, G. (2023, Feb). New Technologies in Diagnosis and Prognosis of Melanocytic Lesions. Retrieved May 01, 2023, from PubMed: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005807/#B13>.



(2023). Retrieved May 01, 2023, from American Academy of Dermatology Association: <https://www.aad.org/member/clinical-quality/guidelines>

(2023). Retrieved Apr 20, 2023, from AIM Specialty Health (Carelon Medical Benefits Management): <https://guidelines.carelonmedicalbenefitsmanagement.com/current-genetic-testing-guidelines/>

(2023). Retrieved May 01, 2023, from Department of Medical Assistance Services: <https://vamedicaid.dmas.virginia.gov/manuals/provider-manuals-library#gsc.tab=0&gsc.q=Pigmented%20lesion%20assay&gsc.sort=>

(2022, Aug 31). Retrieved Feb 06, 2023, from MCG: <https://careweb.careguidelines.com/ed26/index.html>

Chakravarty, D., Johnson, A., Sklar, J., Lindeman, N., Moore, K., & Ganesan, S. (2022, Feb 17). Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. Retrieved Feb 08, 2023, from American Society of Clinical Oncology: <https://ascopubs.org/doi/full/10.1200/JCO.21.02767>

Clinical Laboratory Improvement Amendments (CLIA). (2021, Sep 13). Retrieved Feb 08, 2023, from Food and Drug Administration: <https://www.fda.gov/medical-devices/ivd-regulatory-assistance/clinical-laboratory-improvement-amendments-clia>

Devices at FDA - Next Generation Sequencing. (2023, Feb 06). Retrieved Dec 01, 2022, from Food and Drug Administration: <https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm>

FoundationOne CDx (Foundation Medicine Inc.) for the Intended Use as a Broad Molecular Profiling Tool. (2022, Apr 26). Retrieved Feb 03, 2023, from Hayes, Inc: <https://evidence.hayesinc.com/report/gte.foundationone4467>

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. (2023, Jan 10). Retrieved Feb 06, 2023, from National Comprehensive Cancer Network: [https://www.nccn.org/professionals/physician\\_gls/pdf/genetics\\_bop.pdf](https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf)

Guardant360 (Guardant Health Inc.). (2021, Nov 2021). Retrieved Feb 03, 2023, from Hayes, Inc: <https://evidence.hayesinc.com/report/gte.guardant3767>

Hulick, P. (2022, Aug 10). Next-generation DNA sequencing (NGS): Principles and clinical applications. Retrieved Feb 07, 2023, from UpToDate: [https://www.uptodate.com/contents/next-generation-dna-sequencing-ngs-principles-and-clinical-applications?search=Genetic%20testing%20for%20solid%20tumor%20cancers&source=search\\_result&selectedTitle=3~150&usage\\_type=default&display\\_rank=3#H176019415](https://www.uptodate.com/contents/next-generation-dna-sequencing-ngs-principles-and-clinical-applications?search=Genetic%20testing%20for%20solid%20tumor%20cancers&source=search_result&selectedTitle=3~150&usage_type=default&display_rank=3#H176019415)

LCD: MoIDX: Minimal Residual Disease Testing for Cancer. (2021, Dec 26). Retrieved Feb 03, 2023, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=38779&ver=4>

LCD: MoIDX: Molecular Diagnostic Tests (MDT) (L35025). (2019, Dec 12). Retrieved Feb 06, 2023, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=35025&ver=91&>

LCD: MoIDX: Next-Generation Sequencing for Solid Tumors. (2021, Jun 24). Retrieved Feb 02, 2023, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38045&ver=14&bc=0>

LCD: MoIDX: Plasma-Based Genomic Profiling in Solid Tumors (L38043). (2021, Dec 30). Retrieved Feb 03, 2023, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38043&ver=9&bc=0>

LCD: MoIDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer (L38576). (2021, Jul 18). Retrieved Feb 02, 2023, from Centers for Medicare and Medicaid Services: [https://www.cms.gov/medicare-coverage-Medical 34A](https://www.cms.gov/medicare-coverage-Medical%2034A)



257D,%2522type%2522:%2522all%2522,%2522sources%2522:%255B

(2022). Retrieved Sep 14, 2022, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/search-results.aspx?keyword=Immunoscore&keywordType=starts&areald=s53&docType=6,3,5,1,F,P&contractOption=all&hcpcsOption=code&hcpcsStartCode=0261U&hcpcsEndCode=0261U&sortBy=title>

CLINICAL GUIDELINES GENETIC TESTING. (2022). Retrieved Sep 14, 2022, from AIM Specialty Health: <https://aimspecialtyhealth.com/resources/clinical-guidelines/genetic-testing/>

Colon Cancer with Evidence Blocks. (2022, Apr 07). Retrieved Sep 14, 2022, from National Comprehensive Cancer Network: [https://www.nccn.org/professionals/physician\\_gls/pdf/colon\\_blocks.pdf](https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf)

Colorectal Cancer Prognostication. (2022, Jul 13). Retrieved Sep 14, 2022, from DynaMed: <https://www.dynamedex.com/condition/colorectal-cancer-prognostication>

Compton, C. (2022, Feb 16). Pathology and prognostic determinants of colorectal cancer. Retrieved Sep 14, 2022, from UpToDate: [https://www.uptodate.com/contents/pathology-and-prognostic-determinants-of-colorectal-cancer?search=immunoscore&source=search\\_result&selectedTitle=1~1&usage\\_type=default&display\\_rank=1#H1319388909](https://www.uptodate.com/contents/pathology-and-prognostic-determinants-of-colorectal-cancer?search=immunoscore&source=search_result&selectedTitle=1~1&usage_type=default&display_rank=1#H1319388909)

Efficacy of anti-PD1/PD-L1 immunotherapy in non–small cell lung cancer is dependent upon Immunoscore IC CD8 and PD-L1 status. (2022). Retrieved Sep 14, 2022, from American Society of Clinical Oncology: <https://meetings.asco.org/abstracts-presentations/207422>

Immunoscore® for Colon Cancer. (2022, Sep 14). Retrieved from Veracyte: [https://io.veracyte.com/immunoscore-in-localized-colon-cancer-for-hcp/#clinical\\_validation](https://io.veracyte.com/immunoscore-in-localized-colon-cancer-for-hcp/#clinical_validation)

Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2020, Jul 20). Retrieved Sep 14, 2022, from European Society for Medical Oncology: [https://www.annalsofoncology.org/article/S0923-7534\(20\)39932-4/pdf](https://www.annalsofoncology.org/article/S0923-7534(20)39932-4/pdf)

Procedure Fee Files & CPT Codes. (2022). Retrieved Sep 14, 2022, from Department of Medical Assistance Services: <https://www.dmas.virginia.gov/for-providers/rates-and-rate-setting/procedure-fee-files-cpt-codes/#searchCPT>

25th Edition. (2021). Retrieved Oct 21, 2021, from MCG: <https://careweb.careguidelines.com/ed25/index.html>

(2021). Retrieved Oct 21, 2021, from EncoderPro: [https://www.encoderpro.com/epro/cptHandler.do?\\_k=101\\*81479&\\_a=view&searchTerms=81479&\\_mrad=true&#selected](https://www.encoderpro.com/epro/cptHandler.do?_k=101*81479&_a=view&searchTerms=81479&_mrad=true&#selected)

(2021). Retrieved Oct 21, 2021, from FDA: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/>

A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia. (2018, Dec). Retrieved Oct 21, 2021, from American Association for Cancer Research: [https://cancerres.aacrjournals.org/content/78/24/6762.full?ijkey=1Tjk1xZYFAM6Q&keytype=ref&siteid=aaacrjnl&utm\\_source=Editors%2527%20Picks&utm\\_campaign=7ea1d6ccdc-EMAIL\\_CAMPAIGN\\_2018\\_12\\_14\\_06\\_18&utm\\_medium=email&utm\\_term=0\\_aaaa969146-7ea1d6ccdc-160940133](https://cancerres.aacrjournals.org/content/78/24/6762.full?ijkey=1Tjk1xZYFAM6Q&keytype=ref&siteid=aaacrjnl&utm_source=Editors%2527%20Picks&utm_campaign=7ea1d6ccdc-EMAIL_CAMPAIGN_2018_12_14_06_18&utm_medium=email&utm_term=0_aaaa969146-7ea1d6ccdc-160940133)

Acute Myeloid Leukemia. (2021, Mar 2). Retrieved Oct 21, 2021, from National Comprehensive Cancer Network - NCCN Guidelines: [https://www.nccn.org/professionals/physician\\_gls/pdf/aml.pdf](https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf)

Approach to the patient with neutrophilia. (2021, Jan 4). Retrieved Oct 21, 2021, from UpToDate: [https://www.uptodate.com/contents/approach-to-the-patient-with-neutrophilia?search=CSF3R%20gene%20mutation&source=search\\_result&selectedTitle=4~150&usage\\_type=default&display\\_rank=4](https://www.uptodate.com/contents/approach-to-the-patient-with-neutrophilia?search=CSF3R%20gene%20mutation&source=search_result&selectedTitle=4~150&usage_type=default&display_rank=4)

CSF3R. (2021). Retrieved Oct 21, 2021, from Invitae: [https://www.invitae.com/en/physician/genes/21423/#info-panel-assay\\_information](https://www.invitae.com/en/physician/genes/21423/#info-panel-assay_information)

CSF3R Exon 14 and 17 Mutation Detection. (2021). Retrieved Oct 21, 2021, from Mayo Foundation for Medical Education and Research (MFMER): <https://www.mayocliniclabs.com/test-catalog/Clinical+and+Interpretive/64604>

CSF3R Mutation Analysis. (2021). Retrieved Oct 21, 2021, from Neogenomics: <https://neogenomics.com/test-menu/csf3r-mutation-analysis>

CSF3R Mutations are frequently associated with abnormalities of RUNX1, CFBF, CEBPA, and NPM1 genes in acute myeloid leukemia. (2018, Jun 22). Retrieved Oct 21, 2021, from American Cancer Society (ACS): <https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.31586>

Leukocytosis - Approach to the Patient. (2021). Retrieved Oct 21, 2021, from Dynamed: [https://www.dynamed.com/approach-to/leukocytosis-approach-to-the-patient#ADDITIONAL\\_TESTING](https://www.dynamed.com/approach-to/leukocytosis-approach-to-the-patient#ADDITIONAL_TESTING)

Local Coverage Determination (LCD): MOLDX: NEXT-GENERATION SEQUENCING Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies L38047. (2021, Jul 8). Retrieved Oct 21, 2021, from CMS LCD: <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38047&ver=9&keyword=Myeloid%20Malignancies&keywordType=all&areald=s53&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=1>

M2062 – Genetic Testing for Acute Myeloid Leukemia. (2020, May 26). Retrieved Oct 21, 2021, from Avalon: [Downloads/AHS%20\\_%20M2062%20\\_%20Genetic%20Testing%20for%20Acute%20Myeloid%20Leukemia%20\(1\).pdf](Downloads/AHS%20_%20M2062%20_%20Genetic%20Testing%20for%20Acute%20Myeloid%20Leukemia%20(1).pdf)

Molecular Testing of Solid and Hematologic Tumors and Malignancies. (2021, Sep 6). Retrieved Oct 21, 2021, from AIM Specialty Health CLINICAL APPROPRIATENESS GUIDELINES: <https://aimproviders.com/geneticTesting/wp-content/uploads/sites/15/2021/03/GT04-Molecular-Testing-of-Solid-and-Hematologic-Tumors-9-6-2021.pdf>

Myelodysplastic Syndromes. (2021). Retrieved Oct 21, 2021, from NCCN Guidelines: Version 1.2022: [https://www.nccn.org/professionals/physician\\_gls/pdf/mds.pdf](https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf)

Myeloid Molecular Profile (Genoptix) - ARCHIVED Jan 5, 2021. (n.d.). Retrieved Oct 21, 2021, from Hayes: <https://evidence.hayesinc.com/report/gtesyn.myeloid3547>

NCD: Next Generation Sequencing (NGS) 90.2. (2020, Jan 27). Retrieved Oct 21, 2021, from CMS: <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=372&ncdver=2&keyword=90.2&keywordType=all&areald=all&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=1>

Procedure Fee Files & CPT Codes. (2021). Retrieved Oct 21, 2021, from DMAS: <https://www.dmas.virginia.gov/providers/procedure-fee-files-cpt-codes/#searchCPT>

Rare Disease Database. (2021). Retrieved Oct 21, 2021, from National Organization of Rare Disorders: <https://rarediseases.org/?s=aml&submit=>

(2021). Retrieved Jun 30, 2021, from CMS: <https://www.cms.gov/medicare-coverage-database/new-search/search-results.aspx?keyword=ExoDx%20Prostate&keywordType=all&areald=all&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance>

(2021). Retrieved Jun 30, 2021, from EncoderPro: [https://www.encoderpro.com/epro/cptHandler.do?\\_k=101\\*0005U&\\_a=view&searchTerms=0005U&\\_mrad=true&#selected](https://www.encoderpro.com/epro/cptHandler.do?_k=101*0005U&_a=view&searchTerms=0005U&_mrad=true&#selected)

Cancer Facts & Figures. (2021). Retrieved Jun 30, 2021, from American Cancer Society (ACS): <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf>

Clinical Laboratory Improvement Amendments (CLIA). (2020, Feb 25). Retrieved Jun 30, 2021, from FDA: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=882.4250>

ExoDx Prostate (IntelliScore; Exosome Diagnostics Inc.) - ARCHIVED Sep 18, 2020. (n.d.). Retrieved Jun 30, 2021, from Hayes: <https://evidence.hayesinc.com/report/gtsyn.exodx.4548>

ExoDx™ Prostate Test. (2021). Retrieved Jun 30, 2021, from Exosome Diagnostics: <http://www.exosomedx.com/physicians/exodx-prostate-test>

In Vitro Diagnostics. (2019). Retrieved Jun 30, 2021, from FDA: <https://www.fda.gov/medical-devices/products-and-medical-procedures/in-vitro-diagnostics>

Local Coverage Determination (LCD): MoIDX: Molecular Diagnostic Tests (MDT) (L35025). (2019, Dec 12). Retrieved Jun 30, 2021, from CMS LCD: <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?lcdid=35025&ver=91&bc=CAAAAAAAAAAAAA>

Molecular prognostic tests for prostate cancer. (2021, Feb 24). Retrieved Jun 30, 2021, from UpToDate: [https://www.uptodate.com/contents/molecular-prognostic-tests-for-prostate-cancer?search=Prostate%20biomarker&source=search\\_result&selectedTitle=4~150&usage\\_type=default&display\\_rank=4](https://www.uptodate.com/contents/molecular-prognostic-tests-for-prostate-cancer?search=Prostate%20biomarker&source=search_result&selectedTitle=4~150&usage_type=default&display_rank=4)

Molecular Testing of Solid and Hematologic Tumors and Malignancies. (2021, May 10). Retrieved Jun 30, 2021, from AIM Clinical Appropriateness Guidelines: <https://aimproviders.com/geneticstesting/wp-content/uploads/sites/15/2021/01/GT04-Molecular-Testing-of-Solid-and-Hematologic-Tumors-5-10-2021.pdf>

PCA3 Detection Test For Prostate Cancer - ARCHIVED Jun 7, 2018. (n.d.). Retrieved Jun 30, 2021, from Hayes 2: <https://evidence.hayesinc.com/report/gte.pca1775>

Position Statement: Genomic testing in prostate cancer. (2018). Retrieved Jun 30, 2021, from American Association of Clinical Urologists (AACU): [https://aacuweb.org/docs/position-statements/ps\\_genomic-testing-in-prostate-cancer.aspx](https://aacuweb.org/docs/position-statements/ps_genomic-testing-in-prostate-cancer.aspx)

Proposed Local Coverage Determination (LCD): MoIDX: Biomarkers to Risk-Stratify Patients at Increased Risk for PROSTATE Cancer (DL38985). (2021). Retrieved Jun 30, 2021, from CMS LCD: <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?lcdid=38984&ver=7&keyword=ExoDx%20Prostate&keywordType=all&areald=all&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=AAAAAAQAAAAA&KeyWordLookUp=D>

Prostate Cancer - PCA3 Gene (A-0855), 25th Edition. (2021). Retrieved Jun 30, 2021, from MCG: <https://careweb.careguidelines.com/ed25/index.html>

Prostate Cancer. (2021). Retrieved Jun 30, 2021, from European Association of Urology (EAU): <https://uroweb.org/guideline/prostate-cancer/#5>

Prostate Cancer. (2021, Feb 17). Retrieved Jun 30, 2021, from National Comprehensive Cancer Network - NCCN Guidelines: [https://www.nccn.org/professionals/physician\\_gls/pdf/prostate.pdf](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf)

Prostate Cancer Screening. (2021). Retrieved Jun 30, 2021, from Dynamed: <https://www.dynamed.com/prevention/prostate-cancer-screening>

Provider Manuals. (2021). Retrieved Jun 30, 2021, from DMAS: <https://www.virginiamedicaid.dmas.virginia.gov/wps/portal/transmittals>

(2020). Retrieved May 13, 2020, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/search/search-results.aspx?SearchType=Advanced&CoverageSelection=Both&NCSelection=NCA%7cCAL%7cNCD%7cMEDCAC%7cTA%7cMCD&ArticleType=BC%7cSAD%7cRTC%7cReg&PolicyType=Both&s=53&KeyWord=TSC2&KeyWordLookUp=Doc&KeyWo>

(2020, Jun 24). Retrieved Jun 03, 2021, from MCG: <https://careweb.careguidelines.com/ed24/index.html>

(2021). Retrieved Jun 03, 2021, from Department of Medical Assistance Services: <https://www.dmas.virginia.gov/providers/general-information/procedure-fee-files-cpt-codes/#searchCPT>

Decipher Prostate Biopsy (Decipher Biosciences). (2021, Apr 18). Retrieved Jun 03, 2021, from Hayes, Inc: <https://evidence.hayesinc.com/report/gte.decipher4623>

Decipher Prostate RP (Decipher Biosciences). (2021, Apr 18). Retrieved Jun 02, 2021, from Hayes: <https://evidence.hayesinc.com/report/gte.decipher3356>

Feng, F., & al, e. (2021, Apr 01). Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. Retrieved Jun 03, 2021, from PubMed: <https://pubmed.ncbi.nlm.nih.gov/33570548/>

LCD: MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease (L38292). (2020, Nov 08). Retrieved Jun 03, 2021, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?lcdid=38292&ver=8&keyword=Decipher&keywordType=starts&areald=s53&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=AAAAAAQAAAAA&KeyWordLookUp=Doc&Ke>

Management of Localized or Locally Advanced Prostate Cancer. (2021, Jan 04). Retrieved Jun 06, 2021, from DynaMed: [https://www.dynamed.com/management/management-of-localized-or-locally-advanced-prostate-cancer#TOPIC\\_XJ3\\_DYQ\\_2NB](https://www.dynamed.com/management/management-of-localized-or-locally-advanced-prostate-cancer#TOPIC_XJ3_DYQ_2NB)

Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. (2019, Dec 12). Retrieved Jun 03, 2021, from American Society of Clinical Oncology: <https://ascopubs.org/doi/full/10.1200/JCO.19.02768>

Molecular Testing of Solid and Hematologic Tumors and Malignancies. (2021, Sep 06). Retrieved Jun 03, 2021, from AIM Specialty Health: <https://aimproviders.com/geneticstesting/wp-content/uploads/sites/15/2021/03/GT04-Molecular-Testing-of-Solid-and-Hematologic-Tumors-9-6-2021.pdf>

Prostate Cancer with Evidence Blocks. (2021, Mar 19). Retrieved Jun 03, 2021, from National Comprehensive Cancer Network: [https://www.nccn.org/professionals/physician\\_gls/pdf/prostate\\_blocks.pdf](https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf)

Ross, A., D'Amico, A., & Freedland, S. (2021, Feb 24). Molecular prognostic tests for prostate cancer. Retrieved Jun 03, 2021, from UpToDate: [https://www.uptodate.com/contents/molecular-prognostic-tests-for-prostate-cancer?search=Decipher%20prostate&source=search\\_result&selectedTitle=1~150&usage\\_type=default&display\\_rank=1#H40176779](https://www.uptodate.com/contents/molecular-prognostic-tests-for-prostate-cancer?search=Decipher%20prostate&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H40176779)

(2021). Retrieved May 10, 2021, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/new-search/search-results.aspx?keyword=SelectMDx&keywordType=starts&areald=s53&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all>

Hoffman, R. (2021, May 03). Screening for prostate cancer. Retrieved May 10, 2021, from UpToDate: [https://www.uptodate.com/contents/screening-for-prostate-cancer?search=prostate%20screening&source=search\\_result&selectedTitle=1~150&usage\\_type=default&display\\_rank=1#H3435615414](https://www.uptodate.com/contents/screening-for-prostate-cancer?search=prostate%20screening&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H3435615414)

Molecular Testing of Solid and Hematologic Tumors and Malignancies. (2021, May 10). Retrieved May 10, 2021, from AIM Specialty Health: <https://aimgspecialtyhealth.com/resources/clinical-guidelines/>

Prostate Cancer. (2020, Dec 22). Retrieved May 11, 2021, from DynaMed: <https://www.dynamed.com/condition/prostate-cancer>

Prostate Cancer Early Detection. (2021, Jan 05). Retrieved May 10, 2021, from National Comprehensive Cancer Network: [https://www.nccn.org/professionals/physician\\_gls/pdf/prostate\\_detection.pdf](https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf)

Raja, N., Russell, C., & George, A. (2018, Sep). Urinary markers aiding in the detection and risk stratification of prostate cancer. Retrieved May 11, 2021, from PubMed: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178315/>

Retired: Proposed LCD: MoIDX: SelectMDx for Prostate Cancer (DL38242). (2020, Aug 14). Retrieved May 11, 2021, from Centers for Medicare and Medicaid Services: [https://localcoverage.cms.gov/mcd\\_archive/view/lcd.aspx?lcdInfo=38241%3a4](https://localcoverage.cms.gov/mcd_archive/view/lcd.aspx?lcdInfo=38241%3a4)

SelectMDx for Prostate Cancer (MDxHealth Inc.). (2021, Feb 25). Retrieved May 10, 2021, from Hayes, Inc.: <https://evidence.hayesinc.com/report/gte.selectmdx3769>

SelectMDx for Prostate Cancer. (2021). Retrieved May 10, 2021, from MDxHealth: <https://mdxhealth.com/selectmdx-physician/#overview>

Visser, W., de Jong, H., Mulders, P., & Schalken, J. (2020, Dec). Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis. Retrieved May 11, 2021, from PubMed: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765473/>

(2020, Jun 24). Retrieved May 10, 2021, from MCG: <https://careweb.careguidelines.com/ed24/index.html>

(2021). Retrieved May 10, 2021, from Virginia Premier: <https://www.virginiapremier.com//medical-payment-guidelines/>

(2021). Retrieved Apr 19, 2021, from Virginia Premier: <https://www.virginiapremier.com//medical-payment-guidelines/>

(2021, Mar 12). Retrieved Apr 12, 2021, from MCG: <https://careweb.careguidelines.com/ed24/index.html>

Aaberg, T. M., Covington, K. R., Tsai, T., Shildkrot, Y., Plasseraud, K. M., Alsina, K. M., . . . Monzon, F. A. (2020, Oct). Gene Expression Profiling in Uveal Melanoma: Five-Year Prospective Outcomes and Meta-Analysis. Retrieved Apr 19, 2021, from PubMed: <https://pubmed.ncbi.nlm.nih.gov/33123530/>

Berry, D., & Materin, M. (2017, Jul). Gene Expression Profiling in Uveal Melanoma. Retrieved Apr 19, 2021, from American Academy of Ophthalmology: <https://www.aao.org/eyenet/article/gene-expression-profiling-in-uveal-melanoma>

Berry, D., Seider, M., Stinnett, S., Mruthyunjaya, P., Scheffler, A. C., & Consortium, O. O. (2019, Jun). RELATIONSHIP OF CLINICAL FEATURES AND BASELINE TUMOR SIZE WITH GENE EXPRESSION PROFILE STATUS IN UVEAL MELANOMA: A Multi-institutional Study. Retrieved Apr 19, 2021, from PubMed: <https://pubmed.ncbi.nlm.nih.gov/29578940/>

DecisionDx-UM (Castle Biosciences Inc.). (2020, Jun 17). Retrieved Apr 19, 2021, from Hayes, Inc.: <https://evidence.hayesinc.com/report/gte.decision2107>

Harbour, J. W., & Shih, H. A. (2021, Jan 04). Initial management of uveal and conjunctival melanomas. Retrieved Apr 19, 2021, from UpToDate: [https://www.uptodate.com/contents/initial-management-of-uveal-and-conjunctival-melanomas?search=uveal%20melanoma&source=search\\_result&selectedTitle=1~28&usage\\_type=default&display\\_rank=1#H3466603976](https://www.uptodate.com/contents/initial-management-of-uveal-and-conjunctival-melanomas?search=uveal%20melanoma&source=search_result&selectedTitle=1~28&usage_type=default&display_rank=1#H3466603976)

J., S. R., & Fisher, D. E. (2021, Mar 11). The molecular biology of melanoma. Retrieved Apr 19, 2021, from UpToDate: [https://www.uptodate.com/contents/the-molecular-biology-of-melanoma?sectionName=Uveal%20melanomas&search=uveal%20melanoma&topicRef=7617&anchor=H219772&source=see\\_link#H219772](https://www.uptodate.com/contents/the-molecular-biology-of-melanoma?sectionName=Uveal%20melanomas&search=uveal%20melanoma&topicRef=7617&anchor=H219772&source=see_link#H219772)

LCD: MoIDX: DecisionDx-UM (Uveal Melanoma) (L37033). (2019, Oct 31). Retrieved Apr 19, 2021, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?lcdid=37033&ver=24&keyword=Melanoma&keywordType=starts&areald=s53&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=AAAAAAQAAAAA&KeyWordLookUp=Doc&K>

Melanoma: Uveal. (2021, Apr 08). Retrieved Apr 19, 2021, from National Comprehensive Cancer Network: [https://www.nccn.org/professionals/physician\\_gls/pdf/uveal\\_blocks.pdf](https://www.nccn.org/professionals/physician_gls/pdf/uveal_blocks.pdf)

Molecular Testing of Solid and Hematologic Tumors and Malignancies. (2021, Feb 08). Retrieved Apr 19, 2021, from AIM Specialty Health: <https://aimproviders.com/geneticstesting/wp-content/uploads/sites/15/2021/01/GT04-Molecular-Testing-of-Solid-and-Hematologic-Tumors-2-2021.pdf>

Uveal Melanoma. (2018, Nov 30). Retrieved Apr 19, 2021, from DynaMed: <https://www.dynamed.com/condition/uveal-melanoma>

(2021). Retrieved Feb 9, 2021, from EncoderPro: [https://www.encoderpro.com/epro/cptHandler.do?\\_k=101\\*81521&\\_a=viewDetail](https://www.encoderpro.com/epro/cptHandler.do?_k=101*81521&_a=viewDetail)

70-Gene Signature as an Aid to Treatment Decisions. (2016, Aug 25). Retrieved Feb 9, 2021, from The New England Journal of Medicine: <https://www.nejm.org/doi/pdf/10.1056/NEJMoa1602253>

Breast Cancer. (2019). Retrieved Feb 10, 2021, from American Society of Clinical Oncology (ASCO): <https://www.asco.org/research-guidelines/quality-guidelines/guidelines/breast-cancer>

Breast Cancer. (2021, Jan 15). Retrieved Feb 10, 2021, from National Comprehensive Cancer Network - NCCN Guidelines: [https://www.nccn.org/professionals/physician\\_gls/pdf/breast\\_blocks.pdf](https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf)

Breast Cancer Gene Expression Assays (A-0532), 24th Edition. (2021). Retrieved Feb 10, 2021, from MCG: <https://careweb.careguidelines.com/ed24/index.html>

Cancer Genomics. (2021). Retrieved Feb 10, 2021, from National Human Genome Research Institute: <https://www.genome.gov/dna-day/15-ways/cancer-genomics>

CFR - 21CFR866.6040 - PART 866 - IMMUNOLOGY AND MICROBIOLOGY DEVICES. (2020, April 1). Retrieved Feb 9, 2021, from FDA: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=866.6040>

Class II - k062694 - 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY. (2005). Retrieved Feb 9, 2021, from FDA: [https://www.accessdata.fda.gov/cdrh\\_docs/reviews/K062694.pdf](https://www.accessdata.fda.gov/cdrh_docs/reviews/K062694.pdf)

CLINICAL GUIDELINES Molecular Testing of Solid and Hematologic Tumors and Malignancies. (2021, Jan 4). Retrieved Jan 6, 2021, from AIM Clinical Appropriateness Guidelines: <https://aimproviders.com/geneticstesting/wp-content/uploads/sites/15/2020/11/GT04-Molecular-Testing-of-Solid-and-Hematologic-Tumors-1-4-2021.pdf>

Comparing MammaPrint and BluePrint results between core needle biopsy and surgical resection. (2020, Dec 8-11). Retrieved Feb 9, 2021, from San Antonio Breast Cancer Symposium: [https://agenda.com/wp-content/uploads/2020/12/PS6-19\\_SABCS-2020\\_CNB-vs-Resection-Poster\\_FINAL.pdf](https://agenda.com/wp-content/uploads/2020/12/PS6-19_SABCS-2020_CNB-vs-Resection-Poster_FINAL.pdf)

Deciding when to use adjuvant chemotherapy for hormone receptor-positive, HER2-negative breast cancer. (2021, Feb 5). Retrieved Feb 10, 2021, from UpToDate: [https://www.uptodate.com/contents/deciding-when-to-use-adjuvant-chemotherapy-for-hormone-receptor-positive-her2-negative-breast-cancer?search=MammaPrint&source=search\\_result&selectedTitle=2~4&usage\\_type=default&display\\_rank=2](https://www.uptodate.com/contents/deciding-when-to-use-adjuvant-chemotherapy-for-hormone-receptor-positive-her2-negative-breast-cancer?search=MammaPrint&source=search_result&selectedTitle=2~4&usage_type=default&display_rank=2)

Local Coverage Article: Billing and Coding: MoIDX: MammaPrint (A53104). (2019, Oct 24). Retrieved Feb 9, 2021, from CMS LCD 2: <https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleId=53104>

Local Coverage Determination (LCD): MoIDX: Molecular Diagnostic Tests (MDT) (L35025). (2019, Dec 12). Retrieved Feb 9, 2021, from CMS: <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=35025&ver=91&articleId=53104&bc=AAAAAAAAAEEAAA&>

MammaPrint 70-Gene Breast Cancer Recurrence Assay (Agendia) - ARCHIVED Nov 29, 2018. (n.d.). Retrieved Feb 9, 2021, from Hayes: <https://evidence.hayesinc.com/report/gte.mammaPrint2216>

MammaPrint: a test to predict risk of breast cancer recurrence. (2021). Retrieved Feb 9, 2021, from Agendia: <https://agenda.com/mammaPrint/>



Management of Early or Operable Breast Cancer. (2018, Nov 30). Retrieved Feb 10, 2021, from Dynamed: <https://www.dynamed.com/results?q=reconstructive%20surgery>

National Coverage Determination (NCD) for Next Generation Sequencing (NGS) (90.2). (2020, Nov 13). Retrieved Feb 9, 2021, from CMS: <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=372&ncdver=2&ncaid=290&keyword=Molecular+Diagnostic+Tests&keywordType=starts&areald=all&docType=NCA%2cCAL%2cNCD%2cMEDCAC%2cTA%2cMCD%2c6%2c3%2c5%2c1%2cF%2cP&contractOption=all&so>

Physician/Practitioner Manual. (2020, Mar 11). Retrieved Feb 10, 2021, from DMAS: [https://www.virginiamedicaid.dmas.virginia.gov/wps/portal/ProviderManual/!ut/p/z1/jY8xD4lwEIV\\_!wOjvUPQGLcadSCauBjwFIMClibQkIjp\\_PcSXRg97b1830sOCdIgLXolhVNGi3rIV1rdknPMwy2GJ9wfQuQRX-6GsMBjDOKbwC\\_HEegffwKg6fkU6BeSAMna5J9vuM6jtQSy5b20pWUPO9SVc223CTBA7z0rGtGxX](https://www.virginiamedicaid.dmas.virginia.gov/wps/portal/ProviderManual/!ut/p/z1/jY8xD4lwEIV_!wOjvUPQGLcadSCauBjwFIMClibQkIjp_PcSXRg97b1830sOCdIgLXolhVNGi3rIV1rdknPMwy2GJ9wfQuQRX-6GsMBjDOKbwC_HEegffwKg6fkU6BeSAMna5J9vuM6jtQSy5b20pWUPO9SVc223CTBA7z0rGtGxX)

POLICY – MPP – 024 Diagnostic Genetic Testing of Potentially Affected Individual. (2020, Sept 25). Retrieved Feb 10, 2021, from Virginia Premier: <https://www.virginiapremier.com/wp-content/uploads/MPP-024-genetic-testing-in-potentially-affected-individual.pdf>

Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer Diagnostics guidance [DG34]. (2018, Dec 19). Retrieved Feb 10, 2021, from National Institute for Health and Care Excellence (NICE): <https://www.nice.org.uk/guidance/dg34>

(2020). Retrieved Sep 29, 2020, from National Comprehensive Cancer Network: <https://cse.google.com/cse?cx=007894372670309631110:vocdaeamxuy&ie=UTF-8&q=F1CDx&safe=high>

(2020, Feb 05). Retrieved Sep 29, 2020, from MCG: <https://careweb.careguidelines.com/ed24/index.html>

(2020). Retrieved Sep 29, 2020, from Specialty Association Summary Search: [https://www.google.com/search?q=guideline+for+foundationOne+use&safe=strict&rlz=1C1SQJL\\_enUS876US876&sxsrf=ALeKk03aMJUhOsaDWuQ2vVL2dVCPgA4haw:1601407377144&ei=kYlZX\\_SdCOOpytMPlv2-6Ak&start=40&sa=N&ved=2ahUKEwi0quuui4\\_sAhXjIHIEHZa-D504HhDw0wN6BAgMEEE&biw=1](https://www.google.com/search?q=guideline+for+foundationOne+use&safe=strict&rlz=1C1SQJL_enUS876US876&sxsrf=ALeKk03aMJUhOsaDWuQ2vVL2dVCPgA4haw:1601407377144&ei=kYlZX_SdCOOpytMPlv2-6Ak&start=40&sa=N&ved=2ahUKEwi0quuui4_sAhXjIHIEHZa-D504HhDw0wN6BAgMEEE&biw=1)

(2020). Retrieved Sep 29, 2020, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/search/search-results.aspx?SearchType=Advanced&CoverageSelection=Both&NCSelection=NCA%7cCAL%7cNCD%7cMEDCAC%7cTA%7cMCD&ArticleType=BC%7cSAD%7cRTC%7cReg&PolicyType=Both&s=53&KeyWord=hemolytic+uremic+syndrome&Ke>

Colorectal Cancer Diagnosis and Staging. (2019, Jun 14). Retrieved Sep 29, 2020, from DynaMed: <https://www.dynamed.com/evaluation/colorectal-cancer-diagnosis-and-staging>

De Falco, V., Poliero, L., Vitello, P., Ciardiello, D., & Vitale, P. (2020, Mar). Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania 'Luigi Vanvitelli'. Retrieved Sep 29, 2020, from PubMed: <https://pubmed.ncbi.nlm.nih.gov/32234730/>

FoundationOne CDx - P170019. (2020, Jan 21). Retrieved Sep 29, 2020, from Food and Drug Administration: <https://www.fda.gov/medical-devices/recently-approved-devices/foundationone-cdx-p170019>

FoundationOne CDx (Foundation Medicine Inc.). (2019, Aug 04). Retrieved Sep 29, 2020, from Hayes, Inc.: <https://evidence.hayesinc.com/report/gte.foundationone4467>

Genotype-driven Therapy for Non-small Cell Lung Cancer. (2020, Sep 23). Retrieved Sep 29, 2020, from DynaMed: <https://www.dynamed.com/management/genotype-driven-therapy-for-non-small-cell-lung-cancer>

Hulick, P. (2020, Aug 21). Next-generation DNA sequencing (NGS): Principles and clinical applications. Retrieved Sep 29, 2020, from UpToDate: <https://www.uptodate.com/contents/next-generation-dna-sequencing-ngs-principles-and-clinical->

applications?search=foundation%20one%20testing&sectionRank=1&usage\_type=default&anchor=H3156709146&source=machineLearning&selectedTitle=1~95&display\_rank=1#H31567

Molecular Testing of Solid and Hematologic Tumors and Malignancies. (2020, Sep 01). Retrieved Sep 29, 2020, from AIM Specialty Health: <https://aimproviders.com/genetic-testing/wp-content/uploads/sites/15/2020/08/GT04-Molecular-Testing-of-Solid-and-Hematologic-Tumors-v2.2020.pdf>

MPP – 024 Diagnostic Genetic Testing of Potentially Affected Individual. (2019, Oct 22). Retrieved Sep 29, 2020, from Virginia Premier: <https://www.virginiapremier.com/wp-content/uploads/MPP-024-genetic-testing-in-potentially-affected-individual.pdf>

NCD: Next Generation Sequencing (NGS) (90.2). (2020, Jan 27). Retrieved Sep 29, 2020, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=372&ncdver=2&DocID=90.2&SearchType=Advanced&bc=EAAAAAIAAAA&>

Wu, H., Wany, Z., Zhao, Q., Wang, F., & Xu, R. (2019, Aug 06). Designing gene panels for tumor mutational burden estimation: the need to shift from 'correlation' to 'accuracy'. Retrieved Sep 29, 2020, from PubMed: <https://pubmed.ncbi.nlm.nih.gov/31387639/>

(2020). Retrieved February 14, 2020, from U.S. Food and Drug Administration: <https://search.usa.gov/search?>

(2020). Retrieved February 14, 2020, from Optum360 EncoderPro: <https://www.encoderpro.com/epro/cptHandler.do?>

(2020). Retrieved February 14, 2020, from Department of Medical Assistance Services (DMAS): <http://www.dmas.virginia.gov/#/searchcptcodes>

Assay and Predictive Markers Guidelines. (2015, July 20). Retrieved February 14, 2020, from The American Society of Clinical Oncology (ASCO): <https://www.asco.org/research-guidelines/quality-guidelines/guidelines/assays-and-predictive-markers#/9676>

Chemotherapy for Early and Locally Advanced Breast Cancer. (2018, November 30). Retrieved February 14, 2020, from DynaMed: <https://www.dynamed.com/management/chemotherapy-for-early-and-locally-advanced-breast-cancer#GUID-91CDF50C-5506-4EF1-A4F5-F9D2F053A0B0>

EndoPredict (Myriad Genetics). (2019, June 12). Retrieved February 14, 2020, from Hayes: <https://evidence.hayesinc.com/report/gte.endopredict3972>

EndoPredict. (2019). Retrieved February 14, 2020, from Myriad Genetics, Inc.: <https://endopredict.com/>

EndoPredict Test. (2019, November 6). Retrieved February 14, 2020, from Breastcancer.org: <https://www.breastcancer.org/symptoms/testing/types/endopredict-test>

Evidence Summary: Screening for Breast Cancer. (2016, August). Retrieved February 14, 2020, from U.S. Preventive Services Task Force: <https://www.uspreventiveservicestaskforce.org/Page/Document/evidence-summary-screening-for-breast-cancer/breast-cancer-screening1>

Invasive Breast Cancer: NCCN Guidelines for patients. (2018). Retrieved February 14, 2020, from NCCN: <https://www.nccn.org/patients/guidelines/content/PDF/breast-invasive-patient.pdf>

LCD MoIDX: EndoPredict Breast Cancer Gene Expression Test (L37264) Revision 6 LCD: L37264R006 (MCR), 23rd Edition. (2020). Retrieved February 13, 2020, from MCG: <https://careweb.careguidelines.com/ed23/index.html>

Local Coverage Article: Billing and Coding: MoIDX: ENDOPREDICT Breast Cancer Gene Expression Test (A56963). (2020, January 1). Retrieved February 14, 2020, from CMS: <https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleId=56963&ver=7&SearchType=Advanced&CoverageSelection=Both&NCSelection=NCA%7cCAL%7cNCD%7cMEDCAC%7cTA%7cMCD&ArticleType=BC%7cSAD%7cRTC%7cReg&PolicyType=Both&s=53&Keyword=Endo>

Local Coverage Determination (LCD): MoIDX: EndoPredict Breast Cancer Gene Expression Test (L37264). (2019, November 7). Retrieved February 13, 2020, from CMS1: <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=37264&ver=17&Date=&DocID=L37264&bc=iAAAABAAAA&>

Medicare Benefit Policy Manual Chapter 15 – Covered Medical and Other Health Services 80.1 - Clinical Laboratory Services. (2020). Retrieved February 14, 2020, from CMS2: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>

### Special Notes: \*

This medical policy expresses Sentara Health Plan's determination of medical necessity of services, and they are based upon a review of currently available clinical information. Medical policies are not a substitute for clinical judgment or for any prior authorization requirements of the health plan. These policies are not an explanation of benefits.

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

For specific tests not listed please refer to LCD: MoIDX: Molecular Diagnostic Tests (MDT), L35025 [LCD - MoIDX: Molecular Diagnostic Tests \(MDT\) \(L35025\) \(cms.gov\)](#) and the [DEX \(dexcodes.com\)](#)

### Keywords:

Acute myeloid leukemia, ALK, Analysis, autosomal recessive, BART, BCI, BCR-ABL mutation analysis, Bladder Tumor Marker, BMPR1A, Bone marrow, BRAF, BRCA1, BRCA2, BRCA, Breast cancer, Breast Cancer Index, CALR, Calreticulin Exon 9, cancer prevention, CBFβ/MYH 11, CDH1, CEBPA, ClonoSEQ, Colaris, Colorectal cancer, CSF3R, Decipher, EGFR, Endopredict, Epidermal growth factor receptor, Familial Adenomatous Polyposis (FAP), FLDV, FLT3, gene mutation, gene, genetic test, Guardant 360, Guardant360 CDx, Hardy Zuckerman, HER2, Hereditary retinoblastoma, hereditary, IGH, Immuno Globulin Heavy Chain, JAK2, Juvenile polyposis syndrome, KIT Test, KRAS, Lymphoplasmacytic, Lynch syndrome, Macroglobulinemia, malignant diseases, MammaPrint, MAP, Medullary Thyroid Cancer, MEN1, MEN2, metaplastic, Multiple Endocrine Neoplasia, Mutation Analysis, MYD88, Myeloproliferative Leukemia, MYH-associated polyposis, NMP-22, NPM1, NRAS, Oncotype DX, Ovarian cancer, Pancreatic cancer, Pathfinder TG, PML/RAR Alpha, Prolaris, ProMark, Prostate, PSA, RB1, RET, Signatera, SMAD4, STK11, TP53, UroVysion, VHL, Von Hippel-Lindau syndrome, X-linked recessive

